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ABSTRACT

Greater than 5.5 million fractures are sustained by Americans each year, accounting for
more than 500,000 bone graft surgeries. Bone grafts are the second most transplanted
material, surpassed only by blood. The current “gold standard” for bone grafting involves
harvesting bone material from the patient’s iliac crest, due to its osteoinductive properties.
Unfortunately, the surgery required to harvest material from the iliac crest causes additional
pain for the patient, relies on a limited amount of available bone tissue, and results in, on
average, a 30% rate of donor site morbidity. Both natural and synthetic substitutes have
been developed to avoid complications and alleviate the pain associated with harvesting
grafts from a patient’s healthy bone; however, these substitutes are costly and lack the
osteoinductive properties desired by surgeons for proper repair. Bone tissue engineering
solutions combine scaffold materials with viable stem cells or bone cells in products that can
be implanted into bony defects. Incorporating cells and growth factors within a bone graft
prior to implantation improves upon its ability to induce bone formation and decreases the
time needed for native tissue to proliferate and integrate with the graft. The long-term goal
of this research is to develop a mesenchymal stem cell-based bone graft system with the
potential of someday eliminating the use of autogenic tissue.
The first part of this research project was centered on the order of events of
physiological remodeling: bone resorption by osteoclasts followed by the deposition of
mineralized matrix by osteoblasts. These events indicate that the cells responsible for
resorbing bone mineral may also possess the ability to recruit and/or induce osteoblast
development and activation. A series of studies were developed to gain further insight into
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the role that osteoclasts may play on the differentiation of mesenchymal stem cells (MSCs)
when incorporated into a bone graft system. The results demonstrated that osteoclasts can
positively influence expression of bone cell markers during the initial and final stages of
osteoblast differentiation without having a significant effect on markers linked to the middle
stage. The observed effects on osteoblasts could prove to be advantageous to bone tissue
engineering applications.
A second set of studies were performed to examine the aspirate material obtained from
the femoral shaft using the Reamer/Irrigator/Aspirator (RIA) device (Synthes, USA; Paoli,
PA) as an untapped source of MSCs that could be incorporated into a bone graft system.
The fat layer of aspirate, which has traditionally not been a topic of research or clinical
interest, was the focus of this work. Viable, proliferating cells were successfully and
consistently isolated, using the same techniques, from the fatty layer of RIA aspirate of
multiple patient samples. Further characterization performed on the fat layer from multiple
patient samples showed that the fatty layer of aspirate is mainly composed of four main fatty
acids: oleic, palmitic, linoleic, and stearic. Finally, synthesis of the osteoblast cell markers
alkaline phosphatase and calcium by cells isolated from the RIA fat layer was observed in
both two-dimensional tissue culture polystyrene and three-dimensional ceramic bone graft
granule cultures. The results of this work suggest that the fatty layer of RIA aspirate may be
a new, untapped source for autologous progenitor cells with bone forming capabilities.
Previously considered waste, the lipid rich fat layer of aspirate collected during reaming of
the medullary canal may be a source of adult mesenchymal stem cells that could be used to
stimulate new bone growth at the site of fracture repair.
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PREFACE
Since the 1960s there have been two main approaches toward the repair of damaged or
diseased tissue that lacks the capacity to properly heal by natural means: tissue
transplantation and device implantation. These traditional approaches to bone repair are
currently being integrated with innovative tissue engineering techniques, as researchers and
clinicians shift their treatment focus towards regenerating functional tissue rather than just
filling a defect to provide structural support. One major bone tissue engineering approach
uses a patient’s own cells that are harvested through needle aspiration or from the removal
of bone tissue during surgical reaming. These cells are expanded and incorporated into
implantable systems in hopes of enhancing the bone forming capabilities of traditional bone
graft substitutes.
There are six chapters within this dissertation which describe research studies focused on
the development of a bone graft system that incorporates mesenchymal stem cells with a
synthetic bone graft substitute. The first chapter provides a review of the important cellular
components and functions of bone tissue that must be considered when developing a
successful bone grafting option for treating damaged tissue. Also included in this chapter
are: an explanation of the important features of an ideal bone graft; a brief review of current
natural and synthetic bone graft options; and an overview of the current tissue engineering
approaches to bone graft development.
Chapters 2, 3, and 6 provide the methods, results, and conclusions of studies that
examined how osteoclasts might be used to stimulate the differentiation of mesenchymal
stem cells into bone forming cells. In Chapters 2 and 3, osteoclast conditioned medium was
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applied to mesenchymal stem cells cultured in a two-dimensional system and fed osteogenic
supplements. Results described in the second chapter suggest that the proliferation of stem
cells can be positively influenced by osteoclast conditioned medium. The results from this
research were presented at the Society for Biomaterials Annual meeting in Chicago, IL in
April 2007. The work described in Chapter 3 was conducted to better characterize
osteoclast differentiation within an in vitro test system, and three phases of osteoclasts
differentiation were identified. The results of additional cellular studies, using conditioned
medium collected for each of the phases, also suggested that osteoclast conditioned medium
has a positive effect on the intracellular protein levels of stem cells; however, the overall
differentiation of these cells into osteoblasts was inhibited.
The study described in Chapter 6 also examined the effects of osteoclasts on osteoblast
differentiation; however, the two cell types were co-cultured on a resorbable, threedimensional ceramic bone graft substitute. It was determined that the direct presence of
osteoclasts also had an influence on the development of mesenchymal stem cells into
osteoblasts. These results supported findings from the conditioned medium studies.
Additionally, it was determined that the addition of RANKL to stem cell culture medium,
which is needed to induce osteoclast maturation, may also effect the maturation of
osteoblasts from pre-cursor cells.
The experiments described in Chapter 4 and 5 were the first to examine the fatty layer of
aspirate material collected from reaming of the femoral shaft during fracture repair surgeries.
This work was conducted with the intention of identifying a new source for autologous
mesenchymal stem cells for use within a bone graft system. Cells with morphology
comparable to that of cells from an established mesenchymal stem cell line were successfully
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isolated from the lipid-rich layer and expanded in the laboratory. Additional studies
performed using the isolated cells revealed that the cells acquired from the aspirate were
capable of expressing osteoblast-specific markers when fed osteogenic supplemented
medium during in vitro culture. These data suggest that the aspirate cells may possess
osteogenic potential. These findings were presented at the Society for Biomaterials Annual
meeting in Atlanta, GA in September 2008.
The cells isolated from the reamer aspirate were also tested for their ability to
differentiate into osteoblasts when cultured on ceramic bone graft granules, as described in
Chapter 5. Cells isolated from the aspirate fat layer grew successfully on three-dimensional
ceramic substrates and results from this study served to support the theory that the fatty
portion of RIA aspirate may be an untapped source for progenitor cells that could enhance
bone formation if introduced to the site of fracture repair. The work in Chapter 5 was
presented at the Society for Biomaterials Annual meeting in San Antonio, TX in April 2009.
The experiments presented in this dissertation serve to aid in the future development of
a cell-based bone graft system that may be used in place of the traditional autograft or the
less osteoinductive bone graft substitutes that are available today.
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CHAPTER ONE
INTRODUCTION

1.1 Background and Significance of Problem
Over 2 million bone graft procedures are performed annually worldwide to repair defects
caused by trauma or removal of tumors, or to fuse spinal vertebrae [1]. Bone grafts are the
second most transplanted material into the body, surpassed only by blood, with sales that
have reached over $1 billion and that continue to grow as the global population ages [7, 8].
An array of natural materials and synthetic bone substitutes are currently available to
surgeons needing to perform a bone graft procedure; however, no clinical standard exists for
determining which material or combination of materials may be the optimal choice for
treating specific injuries.
As the life expectancy of humans continues to grow, people are staying active longer.
Since the 1960s there have been two main approaches toward the repair of damaged or
diseased tissue that is unable to heal by natural means: (1) tissue transplantation and (2)
device implantation. Transplantation of tissue from a healthy area on the patient’s own body
to the area in need of repair has been the optimal and preferred method. Implantation uses
materials harvested from donors, or synthetic materials that are designed to interact with
host tissues following placement at the site of trauma [10, 11]. These traditional approaches
to bone repair are currently being integrated with innovative tissue engineering techniques,
as researchers and clinicians shift their treatment focus towards regenerating functional
tissue rather than just filling a defect to provide structural support [12].

Both natural and synthetic materials placed into the body illicit local and systemic
responses from the host. The biological host response differs depending on the material and
can be the main factor in determining whether a treatment succeeds or fails [14]. Surface
chemistry, surface topography, and degradation properties can all affect the biological
response to an implant [15]. Metals are the current material of choice for load-bearing
implants (total joint replacement, fracture fixation) due to their strength and resistance to
fracture fatigue. Metal implants are not ideal, however, because they are not naturally
absorbed by the body and can result in weakening of surrounding host tissue due to major
differences in load distribution [14] or disruption of blood supply [16]. In cases where a
significant amount of bone must be replaced and a metal implant stabilized, the current
available non-metallic materials are: autologous or allogenic bone, polymers, ceramics,
biologically derived proteins, demineralized bone matrix, and composites [17-19].
Autologous and allograft bone are the most widely used materials, with synthetic bone
grafts accounting for only approximately 10% of grafting procedures worldwide [1]. An
ideal bone graft material supports or stimulates [14, 20, 21]:
(i)

Osteointegration - ability of graft material to chemically bond with the surface of
host bone without an intervening layer of fibrous tissue. To be completely
functional the graft must unite with the host bone (e.g. bioglass, hydroxyapatite).

(ii)

Osteoconduction - ability of graft material to support bony and vascular
ingrowth within its structure and onto its surface. The result of this process is an
organized haversian system (e.g. bioglass, hydroxyapatite).
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(iii)

Osteoinduction - ability of graft material to induce differentiation of
mesenchymal stem cells from surrounding tissue into the osteoblast phenotype
(e.g. demineralized bone matrix, biologically derived proteins).

(iv)

Osteogenesis - ability of graft material to induce formation of new bone by
osteoblastic cells present within the graft (e.g. autograft).

While many scaffolding materials can readily facilitate osteoconduction, often growth
factors must be applied to achieve osteoinduction, and progenitor cells must be incorporated
to achieve osteogenesis [18]. Currently, autografts are the only clinically available option that
may have all four characteristics [21]. New tissue engineering techniques, coupled with new
biomaterials, are helping to improve graft options with the potential of some day replacing
the need for the often scarce autogenic tissue.
Bone tissue engineering is a science that combines the knowledge of bone structure,
function and mechanisms of failure with engineering methods to create improved treatment
options for bone repair. Bone tissue is a complex material with a number of structural
features and cellular functions that must be considered when developing a successful bone
grafting option for treating damaged or diseased tissue.

1.2 Structure of Bone Tissue
Bone is a unique connective tissue whose functions in the body are: to support loads
imposed on the body, provide a rigid frame that permits locomotion, protect internal organs
against injury, act as a reservoir for mineral elements, and produce blood cells within the
marrow [22, 23]. Approximately 206 intricately arranged bones are responsible for keeping
the human body upright and for keeping the systems of organs in position despite constant
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movement [24, 25]. The bones are also able to withstand tremendous forces in order to
provide protection for the internal organs. The strength of healthy bone is reported to be
four times stronger than concrete; one cubic inch can withstand loads up to 20,000 pounds
[26]. The efficient arrangement of its elements on the molecular, cellular and tissue
structures provides a relatively low weight material with a tensile strength comparable to cast
iron [27].
Bone tissue is a composite material made up of an inorganic and an organic component.
In general, the inorganic phase accounts for approximately 70% of the total material
composition and the organic phase accounts for the remaining 30% (minus a negligible
amount of water). The two components are tightly bound together and oriented along the
longitudinal axis and the principal direction of stress [27, 28]. Fibrous protein and Type 1
collagen make up 90% of the organic phase; the remaining 10% is mainly noncollagenous
protein filler. Although the exact composition remains unclear, the inorganic component is
primarily made up of crystalline calcium phosphate [27, 29]. Calcium phosphate, chemically
arranged as hydroxyapatite (HA, Ca10 (PO4)6(OH) 2), is responsible for the bones’ rigidity and
resistance to crushing while collagen contributes to its strength and resilience [23]. The
components of the inorganic phase are also responsible for regulating bone metabolism [27].
A number of impurities can be substituted into the phosphate groups that are located on the
apatite lattice [30]. Imperfections in the crystals following these substitutions affect their
solubility, making them more susceptible to the acidic environment created by the bone cells
during the resorption process [27, 29], These substitutions can also affect the density,
morphology, and hardness of the bone [30].
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The major component of the organic phase, the structural protein Type 1 collagen, is
also found in human skin, tendon and dentin. Collagen molecule orientation is said to be
responsible for organizing the deposited apatite crystals parallel to the axis of collagen fibers
[29]. Noncollagenous proteins that contribute to the function of bone are contained within
the collagen matrix (Table 1.1).

Protein

Table 1.1: Major Bone Proteins
Stage of Expression Function

Histone H4

Proliferation

Marker of proliferation; linked to DNA replication [2, 3]

Alkaline Phosphatase

Maturation

Hydrolysis of phosphate esthers and pyrophosphate to I
increase phosphate supply [4]

Osteocalcin

Mineralization

Conversion of protein into calcium; mineral binding;
attraction of osteoclasts; regulation of rate of
mineralization or final shape of mineral crystals [5]

Bone Sialoprotein

Mineralization

Formation and remodeling of connective tissue matrix
[6]

Osteopontin

Mineralization

Initiation of mineralization through calcium-binding
properties [9]

Osteonectin

Mineralization

Help binding of calcium to collagen; binding of
denatured collagen and HA; regulation of Ca+
concentration; organization of mineral within the matrix
[9, 13]

1.3 Bone Cells
The major cell types that occupy bone tissue have different origins and respond to
different stimuli [31]. Unlike man-made materials, bone is self renewing and can adapt to
differing mechanical stresses and strains [27]. The bone cells are able to adapt by forming or
resorbing bone tissue as needed. Mechanical loading is required in order to maintain a

5

healthy balance of mineralization and resorption within the tissue. Successful bone
formation depends on

Figure 1.1: Physiological Arrangement of Bone Cells [32]

the expression of and exposure to a number of growth factors and proteins [33]. Three
bone cell types (osteoblasts, osteoclasts and osteocytes) are constantly interacting as part of
over one million bone remodeling units that are present in the human skeleton (Figure 1.1)
[34].

1.3.1 Osteoblasts
Osteoblasts are cells derived from mesenchymal stem cells (MSCs) that differentiate
along the osetoblastic lineage following expression of certain transcription factors. These
MSCs are located in the bone marrow and within the periosteum. They are polarized with
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nuclei located at the end of the cell, distal to the bone surface [27]. Osteoblasts line the
surface of the bone and contain three major organelles; the nucleus, the Golgi apparatus, and
the rough endoplasmic reticulum. Alkaline phosphatase is found on the surface of the cell
membrane and, as this becomes mineralized, the osteoblasts mature into osteocytes [27].
Osteoblasts change shape as their function changes; growing larger and more rounded as the
level of metabolic activity increases. After the cells are committed along the bone cell
pathway, they secrete alkaline phosphatase and unmineralized bone matrix that forms the
osteoid during maturation. Finally, this osteoid mineralizes to yield mature bone which
expresses osteocalcin. As these new bone cells become embedded in the surrounding tissue
matrix and generate processes, they form the osteocytes that comprise the majority of the
bone cells [24, 27].
The differentiation of osteoblasts from MSCs is a complex process that is dependent on
a number of transcription and growth factors [33]. Differentiation of these cells in vitro
requires supplementing cell growth medium with L-ascorbic acid (Vitamin C) and β-glycerol
phosphate [35, 36]. Ascorbic acid enhances the extracellular matrix deposition through
collagen production and promotes alkaline phosphatase activity [37, 38]. The phosphate
additive is connected to an increased presence of hydroxyapatite [37]. A third supplement,
corticosteroid dexamethasone, has been shown to contribute to increasing the differentiation
potential of MSCs but it may do so while inhibiting proliferation [33, 34, 39]. Expression of
the transcription factor runt-related transcription factor 2 (Runx2), also known as core
binding factor alph1 (Cbfa1), is also required for MSCs to commit to the osteoblast lineage
[40-42]. Runx2 must bind to the promoter of several bone-specific genes, including
osteopontin and osteocalcin, for proper skeletal growth. When expression of this
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transcription factor is repressed in controlled experiments the result is bone development
with symptoms of skeletal dysplasia [41-43].
The differentiation of MSCs into osteoblasts has been divided into three distinct phases
that can be identified by examining the expression of specific genetic markers that are
expressed during the differentiating process (Figure 1.2). The three main phases have been
designated proliferation, maturation, and mineralization [44]. Although an exact map of gene
expression is unknown, the three stages have been identified using the following markers:
Runx2, Type 1 collagen, osteocalcin, alkaline phosphatase, and bone sialoprotein [45].
During the initial proliferation phase, Runx2, Dlx5 and Msx2 are required to steer the
cells away from an adipocytic or chondrocytic phenotype and toward an osteoblastic
phenotype [31]. Expression of the gene histone H4 (H4) is prominent during this phase of
active cell replication and gradually tapers off as the stem cells progress into the maturation
phase [46, 47]. Histones are proteins located within the chromatin of the nucleus whose
synthesis is linked to DNA replication [47]. Type 1 collagen is also expressed in this phase
but its levels peak as the cells start laying down matrix in the maturation stage. This second
phase has been shown to correlate with high levels of alkaline phosphatase expression at
approximately Day 14 after exposure to differentiation cocktail [34]. Type 1 collagen
contains a RGD sequence that may help attract other osteoblasts, and alkaline phosphatase
may contribute to supplying phosphate for the matrix through hydrolyzation of phosphate
esters [34].
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Figure 1.2: Gene Expression During Osteoblast Differentiation
Bone sialoprotein (BSP) is a primary marker for terminally differentiated osteoblasts in
the mineralization phase [48]. Osteocalcin is an additional marker of the final mineralization
phase. Studies of the BSP gene have shown that it helps control osteoblast differentiation
via an autoregulation mechanism. This mechanism uses a positive feedback loop that
contains the BSP promoter [48]. BSP along with osetopontin can contribute to
mineralization via calcium binding [34].
Mature osteoblasts regulate bone formation and stimulate bone resorption through a
signaling triad formed by the molecules receptor activator of nuclear factor kB (RANK),
RANK-ligand (RANKL), and osteoprotegerin (OPG) (Figure 1.2). Of this triad, RANK-L
and OPG are found on the surface of and expressed by osteoblasts, respectively. When
osteoblasts and osteoclasts precursor cells are in physical contact with each other, this
activation can occur [49].
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1.3.2 Osteocytes
As the surface of the osteoblast is covered in mineralized bone matrix, the nucleus
expands. When the terminally differentiated osteoblast is completely surrounded by the
mineralized matrix it is considered an osteocyte [50]. Osteocytes are the most numerous of
the bone cells, accounting for 90% of all the cells in this skeletal tissue [27]. Described as
star-shaped, they are found between the lamellae, arranged around the central lumen [27].
They have an extensive network of processes that allow the cells to establish contact with
surrounding osteocytes and the bone lining cells. It is believed that the cell-to-cell contact
allows the osteocytes to communicate stress and strain signals in order to regulate the
metabolic activity of bone [27].
It is believed that the osteocytes are responsible for sensing mechanical stress and strains
experienced by the bones through integrins that attach these cells to the matrix. Mechanical
forces cause a change in the fluid of the canaliculi which agitate the integrins. Osteocytes
translate the changes experienced by the integrins as biochemical signals to the other bone
cells via gap junctions. These signals act as controls for bone formation or resorption
depending on the loads to which the cells are subjected. Osteocytes can undergo apoptosis
during bone formation and resorption; evidence of these cells living for decades also exists
[50].

1.3.3 Osteoclasts
Osteoclasts are highly specialized macrophage polykaryotic cells that are responsible for
the resorption of old or damaged bone matrix [49]. Unlike osteoblasts, these cells are
derived from the hematopoietic stem cells (HSCs) of the bone marrow that are also
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responsible for the production of monocytes and macrophages. Monocytes migrate to the
surface of the bone and differentiate into mature osteoclasts in response to normal
microdamage that occurs within the bone micro-structure [49], [51]. Osteoclast formation is
complete when the monocytes fuse to form multi-nucleated cells after exposure to stromalderived stimulators.
The multinucleated osteoclasts, or “giant cells”, can be identified histologically by the
large size and ruffled borders that are unique to these cells’ morphology. The ruffled, or
brush, edges are formed by the cell membrane folding in order to increase the cell
membrane surface area [27]. They can also be identified using assays or staining for the
tartrate-resistant acid phosphatase (TRAP) enzyme which osteoclasts produce in elevated
amounts relative to other cell types [52], [53].
A link between osteoclastogenesis and stromal cells was first observed in an in vitro coculture of bone marrow HSCs with stromal cells [52]. Additional studies have shown that
when osteoblast differentiation is absent or impaired in mice, osteoclast formation will not
occur [51]. The discovery of a mechanism that links a receptor located on the osteoclasts
[receptor-activator of NF-κB (RANK)] with a surface protein of osteoblasts [RANK-ligand
(RANKL)] has helped explain the intricate coupling that exist between these two cell types
and their distinct roles in the bone remodeling process (Figure 1.3).
Osteoblast release macrophage colony stimulating factor (M-CSF) stimulates the
production of osteoclast genes in precursors. The presence of M-CSF may also help
facilitate the binding of RANK on the surface of the precursor cells to RANKL which is
produced by and expressed on the surface of osteoblasts [49],[54, 55]. After
RANK/RANKL binding occurs the polarized osteoclast cell undergoes genetic and
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structural changes in preparation of bone resorption. Studies have indicated that membranebound RANKL is more efficient than the soluble RANKL in inducing differentiation of
osteoclasts [54]. This may explain the claim by some that cell-to-cell contact of stromal cells
with pre-osteoclasts is necessary for the production of multinucleated cells [51].

Figure 1.3: Interaction between Osteoblasts and Osteoclasts [56]

Resorption of bone occurs when the brush borders of the osteoclast create a small
pocket with the bone surface and secrete hydrogen ions, creating an acidic environment that
dissolves the bone matrix, exposing collagen bundles [27, 49]. The resorption pits that form
when osteoclasts are active are called Howship’s lacunae. Integrin proteins [vitronectin
receptor (αvβ3)] allow the osteoclasts to attach to the surface of damaged or aged bone and
create an isolated area for ion secretion. Bone material is removed through acidic proteolytic
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digestion [27]. Osteoclasts express the enzymes cathepsin B, D, L, K, and matrix
metalloprotease-1 (MMP-1). Cathepsin K is produced in the largest amounts and is believed
to be responsible for digestion of the bone matrix while MMP-1 is linked to cell migration
[34].
The RANKL signaling pathway has a number of regulatory factors that can control the
activation of osteoclasts when needed to keep bone at a healthy bone mass. A major
regulatory glycoprotein, osteoprotegerin (OPG) is also produced by osteoblasts and is in the
same biological family as RANK and RANKL. OPG acts as an inhibitor of bone resorption
by acting as a decoy receptor for RANKL, blocking the binding of RANK [49], [54]. These
inhibitory mechanisms are used by the body to maintain bone mass and bone density and are
being explored for possible treatment of bone disorders [57]. Clinical use of electromagnetic
stimulation has also been shown to interfere with the RANK-RANKL-OPG triad and could
be applied clinically to help regulate bone resorption [58]. Additional studies have explored
the role RANKL plays in T cell response to various infections; these findings suggest that
RANKL is required for optimal response of these immune cells [59].

1.3.4 Bone Marrow Stem Cells
Stem cells are a unique set of cells that have the capacity for self-renewal and have not
yet committed to a specific cell type [9, 60, 61]. These cells have been shown to be multipotent, meaning that they possess the ability to differentiate into a number of different cell
types. All cells in the body are derived from embryonic stem cells, found in the blastocyst,
during the early stages of human development [9, 61, 62]. Stem cells are driven down
specific paths of differentiation after stimulation by proteins and growth factors that are
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specific to certain cell types. These precursor cells follow a closely regulated chain of
proliferation, migration, and differentiation prior to maturation along most cell lineages [61].
In addition to the embryonic cells, stem cell lines have been identified in the fully developed
adult body (Table 1.2). Locations of these mature stem cell lines include the brain, gut,
epidermis, and the bone marrow [61]. These stem cell lines, often referred to as “adult stem
cells” (ASC), produce specific cell types depending on their location of origin. A number of
recent studies have challenged the idea that adult stem cells are restricted in their ability to
produce a variety of cells types [62]. Marrow stromal cells may represent a source of postnatal stem cells that can be used for production of skeletal and other tissues [63].

Table 1.2: Classes of Stem Cells [61]
Type

Location

Cells Produced

Hematopoietic

Bone Marrow

T-cells, B-cells, white blood cells

Neural

Brain

Neurocytes, oligodendrocytes, blood

Epithelial

Bone Marrow, Gut,
Epidermis

Vascular endothelial cells

Mesenchymal

Bone Marrow

Osteoblasts, chondrocytes,
neurocytes, adipocytes

Embryonic

Blastocyst

All cell types

The stem cells located within the bone marrow can be divided into two major subsets:
hematopoietic and mesenchymal. Bone marrow is widely used as a source for the
mesenchymal stem cells (MSC) [61]. MSCs have been found to exhibit a high degree of
plasticity with the ability to produce osteoblasts, chondrocytes, adipocytes, myotubes and
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neurocytes [61, 64]. When isolated from marrow using plastic, adherent cell culture
techniques, the initial MSCs display a homogeneous population of fibroblast-like cells that
do not express antigens typical of hematopoietic cells (CD34, c-Kit, CD45) [61], [62].
Expanded MSCs subcultured from bone-marrow can contain an assortment of cells that
are at different levels of commitment. Cells isolated from these cultures are not necessarily
homogeneous but include differentiated bone cells and cells that have shown the ability to
develop along multiple lineages (osteo/chondro, osteo/chondro/adipo). As the progenitors
progress they also contain a subset of uncommitted cells and lose the ability of self-renewal
[61].
Another potential source of stem cells in the body that may contribute to formation of
bone cells are found in the adipose tissues [65]. These cells have been also shown to derive
bone, cartilage and neurons, in addition to fat tissue [64]. Cells isolated from the fatty
portion of the bone marrow have demonstrated the ability to mature along both the
adipocyte and osteoblast cell lineages [61]. However, Gimble and coworkers have contested
that although these cells share common functions, an inverse relationship exists between
adipocytes and osteoblasts. They suggest that commitment along one pathway occurs at the
expense of the other phenotype [65].
Bone marrow stem cells isolated from the marrow and the trabecular compartments
have been shown to have the ability to form new bone when transplanted directly. These
cells are also capable of contributing to bone formation when placed in a scaffold culture
prior to implantation into the subcutaneous space in mice and rats [66]. Using these adult
stem cells for the treatment of bone injuries is a major area of interest in orthopedic research
[63]. A number of issues need to be addressed before these cells can be used in clinical
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practice, including defining the optimal stage of commitment of the cells for transplantation
and if they can be introduced to the patient via direct loading at the injury site or through
systemic infusion.
Use of BMSCs for bone regeneration is popular practice because of their multi-lineage
differentiation potential, their relative availability and ease of harvest, and their capacity to
undergo multiple replications without losing multi-potent potential. These traits make them
an attractive source for cell-based therapeutic approaches. Several experiments have
demonstrated that BMSCs can be induced to transform into osteoblasts.
The rates of repair for skeletal defects and the number of MSCs in the body diminish
with age. Human MSCs in bone marrow have been shown to decrease from 1 in 10,000
marrow cells at birth to 1 per 2,000,000 in geriatric patients [67]. These numbers indicate a
correlation between the numbers of available MSCs in the body with the ability of the
skeleton to self-repair. Although the number of available MSCs in the marrow decreases
with age, there has been great success in expanding cultures of these cells in the laboratory to
provide tissue engineering approaches for bone repair.

1.4 Bone Remodeling
The gross outward appearance of bone tissue suggests that it is a dense, homogeneous
and static organ. In reality, bone is a dynamic tissue that undergoes constant resorption,
renewal, and remodeling. Bone resorption and formation are coupled in healthy bone and
occur in a very controlled manner, following a sequence of activation-resorption-formation
[29, 31]. Coupling ensures that new bone will be formed wherever bone is removed [31]. If
functioning properly, up to one-fifth of the skeleton is replaced per year. Briefly,

16

microcracks occur normally on the surface of our bones and osteoclasts are responsible for
the resorption of this damaged material. Resorption creates a cavity similar in size to a
haversion osteon at a rate of 40 to 60 microns per day [29]. Following resorption, the
osteoblasts lay down new bone matrix which becomes mineralized and creates new osteons.
This remodeling mechanism keeps bone mineral new and healthy. When age, trauma, or
a disease disrupts this process there is a resulting imbalance in the formation and resorption
coupling, leaving bones either brittle or fragile. The remodeling process is activated when
the osteoid layer of bone is disrupted and the underlying matrix is exposed. A few concepts
have been developed to explain how this activation occurs: (1) growth factors stored in the
bone matrix are released during resorption and activated by the low pH environment,
allowing them to promote activity by the osteoblast. (2) change in bone topography within
resorption pits is sensed by the bone cells via chemical communication [68].
The group of cells that are involved in activation, resorption, and formation are called a
bone modeling unit (BMU). One proposed model of bone remodeling considers
osteoblasts, osteoclasts and their precursors as part of the BMU [27, 69]. Bone lining cells
that lift from the damaged surface seal off the area that is undergoing remodeling, creating a
‘canopy’ for the other active bone cells [70]. Different areas of the BMU can undergo
resorption and formation simultaneously until the entire area is composed of new
mineralized bone matrix [70].

17

1.5 Natural Bone Graft Options
1.5.1 Autografts
The use of a patient’s own bone continues to be the standard for bone grafting
techniques, despite the availability of numerous bone graft substitutes, due to the intrinsic
osteoinductive capabilities of autograft [71]. Current options for autologous grafts are
vascularized and nonvascularized cortical, cancellous, and bone marrow material. The
current “gold standard” for autogenous bone graft material involves harvesting bone graft
material from the patient’s iliac crest.
Limited numbers of mature osteoblasts are transplanted within the bony material, but
osteogenic precursor cells are present in enough numbers to give the implant the desired
properties that continue to make it the preferred material for bone grafting [18, 21]. Initially,
these grafts act strictly as scaffolds but gradually stimulate bone formation, despite a lack of
vascularization. Ultimate success of the graft depends on the amount and rate of
revascularization that occurs along with new bone growth [27]. Vascularization of cortical
bone grafts ensues at a much slower rate than in cancellous bone grafts; the vascularization
rate affects the chance of cell survival within the graft [72]. Osteoclasts actively resorb
cortical bone grafts, resulting in an increase in porosity that makes them better suited for
osteoconduction [27, 72].
Autogenous bone grafting has an excellent probability of success in spinal fusion, and
cancellous grafts are excellent for nonunions with less than 6cm of bone loss. Cortical bone
grafts have also been successful in larger defects (> 6cm) that require some structural
support [18]. Intraoral autologous grafts are used extensively in periodontal and
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maxillofacial procedures with a high level of success, often in combination with other bone
graft materials [12].
Unfortunately, the surgery required to harvest iliac crest bone graft material causes
additional pain for the patient, draws on a limited amount of tissue, and results in a 30% rate
of donor site morbidity [7, 73]. An insufficient amount of bone available for harvest has
been reported in 20% of surgical cases [8]. Autografts are naturally absorbed by the body,
but this process may occur at a faster rate than new bone formation [74]. Comparing
various implant materials for cranioplasty, autogenous bone grafts have a significantly higher
rate of infection than synthetic titanium meshes [75, 76]. Implant slippage, graft fracture,
and an inability to keep patients immobile for a requisite amount of time have all attributed
to the failure of autografts used in orthopedics [77].
Both natural and synthetic substitutes have been developed to avoid the complications
and pain associated with harvesting autograft material from a patient’s healthy bone, but they
are costly and lack the inductive properties desired by surgeons for proper repair, leaving
autologous tissue as the standard by which all biologics are measured [71, 78].

1.5.2 Allografts
Allografts are products harvested from cadaver bones that have been preserved by flash
freezing or freeze-drying, then vacuum-packed as whole or partial bone, morsels, or chips.
Accounting for approximately one third of bone graft procedures in the United States,
allografts are the preferred substitute for autografts with similar osteointegrative and
osteoconductive characteristics [18]. Allografts contain no living cells, but some grafts are
inductive when demineralized or broken into smaller particles [21, 76]. Allografts are
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advantageous for large defects when inadequate autologous tissue is available for harvest but
must be processed to avoid transmission of disease. The methods used to treat allograft
material prior to use are expensive and increase the cost of this technology while diminishing
the mechanical and biological properties [1].
Allografts have been used successfully for short-level fusions in the cervical spine but are
not recommended for use in the thoracic and lumbar spine due to allograft weakness in
stimulating bone growth [76]. Issues associated with allografts include a 17% rate of
radiological non-union, bacterial infection, and negative immunological response from the
host [21]. Between thirty and sixty percent of allografts experience some complication after
ten years, and a higher level of variability is associated with their use clinically compared to
autografts [14].

1.5.3 Demineralized Bone
Freeze-drying and flash freezing are two commonly used preservation methods that
salvage the mineralized portion of the tissue, however, doing so may increase the chance for
a negative response from the immune system [20]. Demineralized bone matrix (DBM) is a
type of allograft produced by treating bone with hydrochloric acid to remove the mineral
phase, leaving behind only an osteoconductive collagen matrix [79]. Various noncollagenous proteins and growth factors remain within the cortical bone-structured matrix,
which may contribute to the osteoinductive properties of the demineralized material [1, 76].
Both human and bovine DBM are available commercially from a number of manufacturers
and in a variety of forms [80, 81]. Companies claim that specific variations in processing and
storage techniques provide advantages, such as increased concentrations of inductive factors,
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over other competitor products. It is believed that removing the mineralized phase of the
bone increases the exposure and availability of growth factors contained within the material
[20].
The costs of DBM products differ little from synthetic bone grafts, averaging between
$500-$1500 worth of material per surgery (approximately $100-$150 per cubic centimeter)
depending on the amount of material and whether they have been designated as containing
bone morphogenetic proteins (BMPs) [82]. BMPs are found in variable amounts, and the
concentrations are normally so low they probably have very little effect on osteoinduction.
In addition, there is high batch-to-batch variability within DBM products, which can lead to
variable clinical outcomes [83].
DBM is best suited for non-load bearing applications and can be used in place of or as
an autograft extender [81]. Common uses of DBM are for treating bone cysts and wellcontained defects and other bony voids or gaps within the skeletal system [84]. DBM is
often incorporated into a variety of carriers including: putty, paste, strips, and glycerol gels.
The latter forms are intended to keep the DBM in place for ease of implantation. Carriers
include calcium sulfate, collagen, and glycerol. The percentage of actual DBM material
varies between products and is reported to be lower in products that use a carrier [80].
Clinical studies have shown that DBM mixed with autograft is as effective as autograft
alone, in patients undergoing posterolateral spinal fusion [85], where at 24 months, the two
groups had equivalent rates of diffusion. DBM has also been effective, in combination with
internal fixation devices, in treating non-union fractures [86]. The degree of
demineralization has been shown to play a role in the ability of DBM to support osteogenic
differentiation of BMSCs in vitro. Studies have also shown an indirect correlation between
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bone nodule formation and the amount of mineralized tissue that remains in the substrates
[87]. These results illustrate why the variability in batches of DBM is a clinical problem.

1.5.4 Bone Growth Factors
A large number of growth factors have been shown to contribute to bone formation and
repair. As technology improves, new growth factors continue to be identified; however,
much attention is presently being given to the following: transforming growth factor-β1
(TGF-β1), transforming growth factor-α (TGF-α), platelet derived growth factor (PDGF),
fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), insulin-like
growth factor (IGF) and bone morphogenetic proteins (BMP) [33]. Their functions vary
widely but include promotion of vascular ingrowth (FGF, VEGF), induction of osteogenesis
(TGF-β1, BMP), and stimulation of fracture healing (PDGF). The osteoinductivity of DBM
bone grafts has been attributed to the presence of these important growth factors which they
contain [88]. Each of these growth factors has been identified within autografts taken from
the iliac crest. Schmidmaier and coworkers compared levels of osteogenic growth factor in
two sources of autologous bone graft tissue: graft from the iliac crest and bone particles
collected during reaming of the medullary canal [89]. The reaming debris was found to have
higher levels of five growth factors: FGFa (fibroblast growth factor-acidic), PDGF, IGF-1,
TGF-β1, and BMP-2. Significantly greater amounts of FGFb (fibroblast growth factorbasic) and VEGF were measured within the iliac crest material [89]. These results indicate
that reaming debris may be a comparable source of autograft material for use in orthopedic
surgery.
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Attempts have also been made to combine osteogenic growth factors with synthetic
bone graft substitutes in order to improve their osteoinductive capabilities. Clarke and
colleagues studied IGF-1, FGF, and TGF-β1 absorbed onto ceramic bone void filler and
compared to autograft. Of the three, FGF was found to be the most beneficial, but none
had a significant effect on the formation of bone around a metal implant [90].

1.5.5 Bone Morphogenetic Proteins
The use of biologically derived materials as components in bone grafts is a growing area
of interest as more is information is gathered about the functions of growth factors in bone
development. Bone morphogenetic proteins are a subset of the TGF-β super family that
have been isolated for their ability to induce bone formation in vivo [91]. These proteins are
very powerful stimulants for bone formation that are found naturally at sites of bone
formation. More than 16 human BMPs have been identified and numbered accordingly,
with BMP-2 through BMP-9 (with the exception of 8) showing the most promising toward
bone formation. BMP-2 and BMP-7 are the two that have shown to stimulate bone
formation equally or even better than autogenous bone grafts [76, 92]. It is believed that
BMPs induce the expression and function of a number of major proteins including:
osteocalcin, bone sialoprotein, and alkaline phosphatase [91].
At present only a few products have been approved for clinical uses that contain BMPs
but it is an area of active growth (Table 1.3). BMPs are available in small amounts naturally
so scientist have used genetic engineering to produce the quantities that are needed for use
in bone graft products. This technology ensures purity and reproducibility when isolating
the growth factors. Initial work with BMPs for bone repair showed that the product was
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quickly removed by body fluids when placed within the surgical site. As a result, the
approved products use Type 1 collagen as a carrier for ease of delivery. BMPs must be
delivered in the correct dose and over enough time for proper bone formation to occur.
Further development is needed to improve carrier methods. Modifications could potentially
reduce the amount of BMP needed initially, thereby allowing a reduction in the cost of the
products [91]. Currently, for example, 3.5mg of OP-1 Putty from Stryker is sold at a cost of
$4500.
Approval for these biological products was preceded by clinical studies that
demonstrated their success in spinal fusion surgery. BMP-based products can now be used
in tibial fractures as well [91]. Springer and colleagues explored the use of BMP-7 on cranial
defects in growing animals and found that they induced higher quantities of bone growth
over iliac bone grafts [93]. This protein has also successfully prevented non-union formation
when applied immediately after fracture [94]. BMPs combined with HA and collagen gels
have been examined for potential use in dental repair. These composites have the potential
to induce bone formation that can stabilize HA material in mandibular augmentation [72].
A study on the use of BMPs in over 300,000 spinal fusion surgeries in the United States
between 2002 and 2006 was conducted by the Department of Neurosurgery at Brigham and
Women's Hospital in Boston, Massachusetts. The group found that hospital stays and
inpatient costs were increased with the use of BMPs, regardless of the area of the spine
where fusion was performed. Additionally, complication rates for fusions performed in the
neck region were 50% higher in patients when a BMP product was used, compared to when
one was not [95]. The Food and Drug Administration has issued warnings about the use of
BMP products in areas of the neck, an area that is not approved for BMP use.
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Table 1.3 : Clinically Available Bone Morphogenetic Protein
Products
Product Company
Contents
Uses
Form
OP-1 Stryker
Genetically
Spinal fusion Putty
Putty
engineered human Traumatic
BMP-7 powder
fracture
and bovine
collagen
Infuse Medtronic Human BMP-2
Spinal fusion Solution
solution with
Traumatic
collagen sponge
fracture
for delivery
MB52 DePuy
BMP molecule
In clinical
In clinical
Spine
(MP52) combined development development
with calcium
phosphate
synthetic bone
graft substitute
(Healos)
1.6 Synthetic Bone Graft Options
Synthetic bone grafts have been developed to alleviate the complications associated with
the use of human bone as a grafting material. Synthetic grafts are readily available and do
not require the patient to undergo a tissue harvesting procedure, alleviating pain that may
accompany an additional procedure [1]. Traditional synthetic bone grafts are osteointegrative
and osteoconductive, with more recent attempts being made to increase osteoinductivity by
incorporating bone morphogenetic proteins (BMPs) and/or cellular material within the graft
[1]. The creation of a composite graft that combines osteoconductive matrices with a
component containing osteogenic cells and osteoinductive growth factors could alleviate the
use of autografts completely, potentially improving their functionality, speeding the healing
process, and improving the rate of bone replacement.
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Synthetic bone grafts should support new bone formation, support mechanical loads
that are present at the defect site, elicit no foreign-body reaction, cause minimal fibrous
tissue growth, and undergo remodeling by the body [21]. The mechanical properties of the
graft need to be balanced to prevent stress shielding, a problem caused when the material is
too stiff compared to natural bone. The graft must be strong enough to withstand cyclic
loading and resist fatigue fracture [21].
When a synthetic implant is placed inside the body there is an initial acute inflammatory
response that results in the mitotic expansion of mesenchymal cells that produce
extracellular matrix around the implant site. If the implant is made of a metal or metal alloy,
the extracellular matrix forms a fibrous membrane encapsulation around the implanted
material. When a metal orthopedic implant is used within bone, a capsule of functional
regenerated bone tissue rather than a fibrous membrane can form around the implant. The
formation of regenerated bone tissue, with no fibrous interface, is desired to achieve
integration of the implant with the native tissue. In cases where alumina or titanium devices
are used, the interface between the regenerated bone capsule and implant is not strong
enough to withstand high loading, especially in shear [67, 96].
It was first demonstrated by L.L. Hench that certain types of glass ceramics form a
chemical bond between the surface of the implant and the regenerated bone tissue capsule;
making the interface very strong, stable, and able to better withstand loading. Hench
showed that glasses that contained specific portions of oxidized elements were able to form
this chemical bond with the living bone tissue, now referred to as bioactive glasses [10].
After it was reported that these glass substrates had bioactive properties, hydroxyapatite
ceramics and ceramic phosphates were also found to possess this important quality. Not all
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ceramics are bioactive. Since this discovery, a number of ceramics have been used in bone
reconstruction surgery with positive results [10, 11].
Some non-ceramic materials (i.e. aragonite, calcite) and organic polymers (i.e.
polyethylene oxide (PEO) / polybutylene terephthalate (PBT) block polymer Polyactive ®)
have also shown similar bone-bonding characteristics [67, 97].

1.6.1 Ceramic Bone Graft Properties
A number of synthetic, calcium-based materials have been used successfully as bone
grafts due, in part, to their biomechanical properties. Ceramics are an attractive alternative to
natural materials because they are available in virtually unlimited quantities and exhibit a high
degree of purity. Some commercially available products have properties closer to cortical
bone (Norian; Synthes, Inc.) while others are similar to cancellous bone (Vitoss; Orthovita,
Inc.). Others provide no structural capacity in vivo and merely act as cement (MIIG; Wright
Medical Technology) [82].
Synthetic ceramic products are bioinert or bioactive and provide a scaffold into which
the host tissue may grow, but they are not intrinsically osteoinductive. When a ceramic graft
is implanted next to healthy bone, osteoid is secreted directly onto the surface of the material
without interference from fibrous tissue. This new osteoid is capable of mineralization and
subsequent remodeling by the body as the synthetic material degrades over time. The rate of
degradation varies from weeks to years depending on the type of ceramic [72]. Ceramics
also can be used in combination with other bone graft materials to provide enhanced
properties. Surgeons can incorporate drugs or antibiotics into ceramic powders to help fight
infection at a defect site [98].
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The four classes of synthetic ceramic materials listed in Table 1.4 are most commonly
used in orthopedic bone repair [1, 21]. These materials are not always moldable into desired
shapes but have been used in a number of applications including: femoral reconstruction,
spine arthrodesis, filling of cystic cavities and tibial osteotomies, and treatment of
periodontal osseous defects [18].
Bone Graft
Material
Tricalcium
Phosphate

Synthetic
Hydroxyapatite

Coralline
Hydroxyapatite

Calcium sulfate

Table 1.4: Ceramic Bone Graft Substitutes
Important Features
Commercially Available
Product
®
Compressive and tensile strength similar to
Stryker TCP Putty; Stryker
cancellous bone
Gradually removed from the site as new bone is
Cellplex TCP Graft; Wright
formed
Medical Technology
Degraded by osteoclasts
Porosity and handling characteristics less predictable Orthograft; DePuy
than other products
Vitoss; Orthovita, Inc.
Faster resorption and less structural strength than
HA
Structure similar to amorphous biological precursors
to bone
Structure similar to mineralized bone
Apapore; Apatech
Slow resorption rate of 5-15% per year
Much higher compressive strength than cancellous
OpteMX (60% HA);
bone
Exactech Biologics
Fracture prone in shock loading
Predictable and steady rate of absorption and
Calcitite HA; Zimmer
porosity
Dental
Interconnected pore structure similar to cancellous
ProOsteon; Interpore
bone
International
Contains only 20% matrix
Faster bone ingrowth and vascularization than other Interpore 200®; Interpore
ceramic options
International
50-80% filling of void within 3 months
Does not cause significant stress shielding
Biocoral®; Biocoral, Inc.
Plaster of Paris
MIIG® 115; Wright Medical
Dissolves in 5-7 weeks
Technology
No structural properties in vivo
Water soluble
Osteoset; Wright Medical
Technology
DentoGen; Orthogen LLC
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Ceramic materials differ in their resorption rate, porosity, crystallinity, and chemical
composition, depending on the manufacturer and its end-use form (i.e. large blocks,
granules, injectable system, beads, etc.). The structural properties of the various ceramics
influence the host tissue ingrowth. The percent porosity in a material indicates the amount
of surface area available for cellular attachment and also affects the rate of degradation. In
the 1970’s Hulbert and colleagues indicated that pore sizes of at least 45-100μm and up to
500μm were optimal for new bone ingrowth, while 100-150μm pores provide for ingrowth
of fibrovascular tissue [1, 21, 99]. It has been shown that new bone formation occurs within
the internal regions of porous hydroxyapatite (HA) ceramics before forming on the outer
surface of the implant. When the ceramic material is mixed with fresh bone marrow, new
bone mineral is produced by progenitor cells contained within the marrow that attach to the
internal pore surfaces. This sequence of events, ‘bonding osteogenesis’, has been described
by Ohgushi and Caplan and has been found to occur on other ceramic materials including:
tricalcium phosphate (TCP), bioglass, and HA/TCP composites [67]. The porous structure
of a biomaterial contributes to the material’s in vivo performance [100].
Ceramic grafts are subject to resorption by chemical dissolution or digestion mediated by
osteoclasts [101]. Scaffold resorption rates vary between materials and can have an effect on
the regeneration of bone within and surrounding the scaffold [18, 21, 101]. Hing and
coworkers determined, in a 12-week rabbit model, that dense calcium sulfate exhibited a
rapid rate of resorption through chemical breakdown, while ultra porous tricalcium
phosphate was quickly broken down through a combination of cellular resorption and
dissolution. Although the mechanisms of resorption differed, the rapid rate was held
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accountable for the lack of bone regeneration that surrounded each ceramic material. The
ultimate rate of bone regeneration and healing is significantly affected by the rate and
process of ceramic degradation; a stable scaffold is necessary to support new bone and
vascular growth that will replace the ceramic material over time [18, 21, 101].
Ceramics are weak in tension but strong in compression (Table 1.5) [21]; additionally,
they have poor mechanical resistance when used in bulk and have low impact resistance,
tensile strength, and fatigue resistance. The mechanical properties of these implants limit
their use in weight bearing sites; however, ceramics are sometimes used for hip fracture
stabilization and for treating periodontal bone defects [102, 103]. Ceramic bone graft
combined with internal fixation devices have successfully promoted repair of non-union and
difficult fractures[104].
Table 1.5: Mechanical Properties of Bone Graft Materials [21]
Cancellous
___________ Bone

Cortical
Bone

Compressive 5.5
Tensile
3

162
151

Young’s Modulus (GPa)
1

15

Coralline
HA

Porous
HA

Strength (MPa)
9.3
60
2.8
2.5
1.2

9.2

Calcium
Sulfate

Porous
TCP_____

23
4.1

13
-________

-

1.6

TCP and synthetic HA are structurally comparable to human bone [1, 10, 11]. Both
ceramics are virtually bioinert, eliciting minimal response from the body’s immune system
[105]. TCP grafts are resorbed as new bone penetrates the graft; HA, however, is less
resorbable and can remain at an implant site for many years. Following implantation of
TCP, an osteointegrative HA layer forms on the bone-implant interface. Calcium and
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phosphate ions interact between the host tissue and in the implanted material to create a
strong chemical bond [1, 10]. The precipitation of an HA layer on the surface of these
materials in response to the chemical reaction at the surface leads to the adsorption of
proteins and other macromolecules. Cellular attachment is enhanced following these surface
changes that occur on the ceramic [67]. The porous structure also encourages tissue
ingrowth and once the surrounding bone has been incorporated into the implant the
mechanical strength is comparable to cancellous bone [1].

1.6.2 Beta-Tricalcium Phosphate
Tricalcium phosphate (Ca3 (PO4)2) is widely used for orthopedic applications in its beta
form, β-TCP. β -TCP is commercially available in either porous or solid form in granules or
blocks. The calcium-phosphate molar ratio has been reported as 1.5 [106, 107]. This
material is often used as a graft expander with autologous tissue since the replacement
volume of bone is initially less than the amount of β-TCP resorbed within a bone defect
[21]. To study the effect of pore size on β-TCP in vivo characteristics, von Doernberg and
associates implanted eight millimeter diameter cylinders of β-TCP with pore sizes ranging
from 150-1220μm into the cancellous areas in the long bones of sheep[108]. Ceramic
resorption of the implants occurred within the first 6 weeks following implantation and
almost complete bone replacement was seen in radiographs by Week 12. Substrates with a
pore size of 510μm had the fastest resorption; however, the resorption rate had a slightly
negative effect on bone formation [108]. When mixed with bone marrow aspirate (1:1), the
ultraporous β-TCP bone graft substitute Vitoss (Orthovita, Inc.; Malvern, PA), resulted in
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new bone formation that matched the density of existing host cancellous canine bone by 12
weeks in vivo [100, 109].
An ultraporous form of β-TCP uses particles in the nanometer range to better mimic
the structure of naturally occurring cancellous bone. The nanosized particles better mimic
the surface of physiological bone and result in improved osteoconduction; better resorption
of the smaller particles by osteoclasts is associated with this ultraporous structure [1, 100,
110]. When mixed with bone marrow and implanted subcutaneously in rats, ultraporous βTCP has been found to produce more bone and osteoblastic cells than DBM [100]. A
similar mixture exhibited a 91% spinal fusion success rate after 12 months in humans with
degenerative disc disease [111].

1.6.3 Hydroxyapatite
Synthetic HA (C10 (PO4)6(OH) 2) is based on the main mineral component of
physiological bone. The ceramic form is sintered at temperatures between 700 and 1300oC
to create a porous crystalline structure. Pores are created by the addition of hydrogen
peroxide prior to sintering, resulting in bubble formation. This sintering method does not
allow tight control of pore size and connectivity [21]. When packaged as a solid block, HA
has a higher modulus of elasticity than bone. The block form has a calcium-phosphate
molar ratio of 1.67, slightly higher than TCP, and is resorbed at the rate of only 1-15% per
year [1, 106]. Large amounts of HA can remain at a defect site for years after initial
placement [18]. Examination of HA surface roughness and cellular response to the surface
revealed that proliferation, adherence, and detachment strength are all sensitive to the
material’s topography [112]. Due to its cell affinity, hydroxyapatite has been used
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successfully to coat metal implants [21]. Previous studies indicate that when primary or
culture expanded marrow stem cells are placed in porous HA implants for treatment of
segmental defects in rats or canines, the resulting bone regeneration is greater than in defects
treated with the ceramic alone. These data indicate the potential for cellular HA to be used
in reconstruction following benign tumor excisions or intra-articular compression fractures
[67].
Coralline HA capitalizes on the interconnected, consistent pore size, and permeable
structure of marine coral that mimics natural cancellous bone. Coralline HA consists of the
crystalline form of calcium carbonate, without any silica or phosphate, arranged in a
macroporous structure that facilitates both vascular and host tissue ingrowth [67]. Extreme
heat and pressure are used to remove all organic matter from the marine coral, resulting in a
sterile material that is packaged as granules or blocks. Experimental and clinical studies have
shown this product to be highly osteoconductive and capable of excellent vascular ingrowth.
Histological analyses of coralline implants following implantation have shown strong bone
adaptation to the calcium carbonate surface. This surface has the ability to support the
differentiation of MSCs into bone forming cells [67]. When compared to cancellous
autografts, no major differences were seen between the two groups for maintenance of
reduction, time required to union, or range of motion for the knee following metaphyseal
defect repair of displaced tibial plateau fractures. Coralline HA has been shown to possess
improved degradation properties over its synthetic counterpart [1, 67].

1.6.4 Calcium Sulfate
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Commonly known as Plaster of Paris, calcium sulfate is thought to act as a conductive
matrix for ingrowth of blood vessels and osteogenic cells, when implanted adjacent to a
viable periosteum or endosteum [7, 21]. This material dissolves at varying rates and can be
mixed with antibiotics to help fight bone infections. Most commonly used as a bone void
filler, calcium sulfate completely resorbs and the host tissue is able to regain pre-injury
structural properties [18]. Medical grade calcium sulfate is produced with crystals of similar
size and shape [113]. This inexpensive material has been used as a bone void filler for over
100 years and has demonstrated success in the repair of ovine metaphyseal defects [114].

1.7 Tissue Engineering Approach to Bone Graft Development
A key challenge in the area of bone repair is the development of tissue-engineered
products that can be used to treat bone defects [115]. Bone tissue engineering solutions
combine scaffold materials with viable stem or bone cells in products that can be implanted
into massive bony defects [67]. A successful tissue-engineered construct would offer a better
an alternative to the autologous bone graft that is the ‘gold standard’ available today. It is
widely recognized that osteoblasts are important with respect to bony ingrowth of
biomaterials, and the success of a tissue-engineered construct will ultimately depend on how
the construct can be incorporated into the host tissue [116]. The incorporation of osteogenic
cells and growth factors within a bone graft can improve the substitute viability, but the
optimal mix of cells/scaffold/growth factors has yet to be determined [117] and is likely
patient and/or application specific. Although the ultimate viability test is in clinical
application, the success of modular bioreactors is crucial to the development of tissue test
systems with which to model bone cell behavior and bone development [118].
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One major bone tissue engineering approach uses the patient’s own cells to regenerate
lost tissue. These cells can be harvested through needle aspiration or from the removal of
bone tissue during surgical reaming [119]. Cells can then be expanded and incorporated into
an implantable device or injectable system. It is still unknown whether progenitor cells offer
any advantage over terminally differentiated cells for the ultimate success of the device.
Schantz and colleagues performed a direct comparison of progenitor and terminally
differentiated cells seeded onto three dimensional polycaprolactone scaffolds to repair
cranial defects in an animal model. Both cell types formed mineralized bone and exhibited
similar osteogenic capabilities [120].
The discovery and development of successful culture techniques for mesenchymal stem
cells has been a driving factor behind autologous cellular engineering approaches. MSCs that
have been harvested from bone marrow and expanded in vitro may be successfully driven
toward an osteogenic phenotype [121]; conditioned culture medium can have a similar effect
[122]. Cellular differentiation and osteogenic potential of the cultured bone cells is
determined using assays and histological staining techniques that check for the expression of
the major bone proteins represented in Table 1.1 [123]. Ohgushi and Caplan note that,
although MSC densities in bone marrow diminish with age, it is still possible to expand the
cells enough to treat older patients using tissue engineering techniques [67].
Other potential drivers for tissue-engineered bone formation include periosteal and
alveolar bone cells. These alternative cell sources are easily accessible; procedures for
harvesting have been well tolerated by patients, even under local anesthesia [66, 116]. Tests
to compare the bone formation potential of these cell types with MSCS have been executed
using subcutaneous injections in mice. Periosteal cells were most successful in forming bone

35

nodules after 12 weeks when delivered within fibrin glue [66]. Periosteal cells have also been
successful when incorporated within various polymer constructs and used for the repair of
critical-sized calvarial injuries in rabbits [120, 124].
It is also important to note that, although much of the focus is currently on the culture
and production of osteoblasts (bone-forming cells), osteoclasts (bone-resorbing cells) have
an equally crucial role in the maintenance and success of any tissue-engineered construct.
After successful bone formation has been achieved in vivo, the construct must be maintained
through the bone remodeling process. Remodeling is essential to maintaining the mechanical
structure and properties of the native bone tissue [118, 123]. Osteoclasts are the most
important cells that will be involved in resorption of the scaffold matrix, but they are only
found on about 1% of the bone surface [125]. The discovery of the RANK/RANKL
mechanisms has paved the way for successful osteoclast culture in vitro, which allows the
incorporation of these cells into bone graft systems [69, 125].
The ideal scaffold material must: induce cellular growth and new tissue formation,
support vascularization in a timely manner, resorb at a rate consistent with new bone
growth, and be readily sterilized [126]. Any of the currently available bone grafts or graft
substitutes can potentially be used as tissue-engineered scaffolds. The formation of a
mineralized extracellular matrix is the most reliable determinant that a material will induce
and support new bone generation [127]. Ceramics, DBM, and polymers are all being
considered in bone tissue engineering research due to their various material strengths. The
most successful implant may ultimately be a combination of two or more traditional
materials. The scaffold will need to facilitate development that mimics the internal bone
structure physically, biochemically, and mechanically [33].
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Commercially available human cell-based products are still in clinical trials but studies
have already provided the ‘proof of concept’. Cell/HA ceramic scaffold based treatment has
been used successfully for treating long bone segmental defects (4-7cm). When applied with
external fixation for stabilization, no major problems were evident up to 6 years postoperatively [128]. HA ceramics seeded with MSCs and implanted in vivo have displayed
higher compressive strength and energy absorption properties than native tissue following
implantation into cortical bone [121, 129]. A modulus mismatch can result in stress shielding
and be detrimental to the tissue surrounding the implant site. Due to its high strength and
slow rate of degradation, HA is not ideal for all applications, including when treating young
patients or when repairing weight-bearing sites. This scaffold material can remain unchanged
for many years after successful functional recovery, even with the incorporation of cells
[105]. Tricalcium phosphate has a much faster rate of degradation and has been shown to
successfully supported the growth of bone tissue in vitro [105]. High total porosity and pore
interconnectivity are thought to be necessary scaffold characteristics for use in tissueengineered bone graft product. [105]. The use of MSCs cultured onto the surface of nonbioactive materials in order to improve upon implantation success has also been explored.
This “osteogenic matrix coating” technique is most useful in total joint and femur
replacement surgeries, but offers a solution to combat loosening of any metal implant [67].
A major area of concern in both the clinic and the laboratory is the development of a
treatment option for large bone defects. If a defect is too large (>2cm) there is often not
enough autogenic bone available for harvest. The use of allografts and other bone graft
substitutes has not been as successful in these critical size defects, mostly due to inadequate
vascular tissue growth [130]. Angiogenesis is a necessary precursor for complete
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osteogenesis and must be achieved throughout a bony defect in order to facilitate proper
bone repair. Creating tissue-based implants with enough mechanical strength for load
bearing applications and improving control of stem cell differentiation are additional areas of
focus, necessary to improve treatment options.

1.8 Aim of Research
A successful tissue-engineered construct strives to offer a more desirable alternative to
the autologous bone grafts that are currently the preferred choice of surgeons. The
incorporation of cells and growth factors within a synthetic bone graft may improve its
performance; but an optimal, robust mix of cells, scaffold, and growth factors has yet to be
determined [14, 131]. The aim of this research was to develop a biologically active bone
graft system based on knowledge of bone cells and their inter-relationships. It is
hypothesized that osteoclasts play an important role in the recruitment of mesenchymal stem
cells (MSCs) to areas of bone resorption and their presence will have an effect on the
differentiation of osteoblasts [38, 132]. The natural pattern of bone formation following
bone resorption was the basis for the experimental design. Specifically, the goal for the first
set of experiments was to determine how the development of osteoblasts from stromal stem
cells was affected by: (1) medium collected from osteoclast cultures and (2) direct coculture
with osteoclasts. Additionally, it is believed that the aspirate material obtained from the
femoral shaft using the Reamer/Irrigator/Aspirator (RIA) device (Synthes, USA; Paoli, PA)
is a potential source of mesenchymal stem cells (MSCs) with osteogenic potential. The
reamer aspirate may be an untapped source for autologous progenitor cells that could aid in
bone formation when incorporated into bone grafts. Hence the goal of the second set of
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experiments was to isolate cells isolated from the fat layer of reamer aspirate and examine
them for osteogenic potential, using 2-D and 3-D surfaces. Together, the two sets of
experiments provide important information toward the construction of a clinically relevant
bone tissue engineering device and provide important information toward the assessment of
bone tissue engineering devices in an in vitro test system setting.
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CHAPTER TWO
EFFECT OF OSTEOCLAST CONDITIONED MEDIUM ON OSTEOBLAST
DIFFERENTIATION FROM STROMAL CELLS

2.1 Background
Bone is a dynamic tissue that is constantly renewing itself in order to maintain its internal
structure and mechanical properties [1, 2]. Bone tissue remodeling occurs in response to the
internal and external stresses that are applied to the body. Osteocytes, osteoclasts, and
osteoblasts are the three cell types that interact as part of more than one million bone
remodeling units that are at work within the human skeleton. Of these three, osteoblasts
(bone forming cells) and osteoclasts (bone resorbing cells) have opposing roles, but work
together through an interconnected mechanism referred to as “coupling” to continuously
remodel the bone tissue (Figure 2.1). The interaction between these two cell types during
the coupling process is responsible for keeping the bone mineral new and healthy [3, 4].
Osteoblasts develop from multi-potent mesenchymal stem cells (MSCs) and have been
successfully isolated from various parts of the body including the bone marrow, bone tissue,
and adipose tissue [5-7]. Numerous researchers have shown that following isolation, MSCs
maintained in a laboratory environment can be appropriately stimulated to successfully
proliferate, differentiate, and express genes consistent with the osteoblast phenotype (Figure
1.2). These genes include but are not limited to: alkaline phosphatase, osteocalcin, and bone
sialoprotein [8-10]. Ultimately, MSCs cultured in vitro are able to secrete mineralized matrix
when full maturation is achieved, making them an attractive option to consider for use in
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orthopedic clinical devices. These osteoblast precursor cells present a potential means of
improving the osteoinductive properties of current bone graft materials.
The incorporation of MSCs into tissue-engineered bone grafts is of great interest for use
in orthopedic, dental, and craniofacial applications [6, 8, 11]. Korda and coworkers found
that significantly more bone was formed around titanium hip stems implanted into sheep
when the stems were stabilized with an allograft/MSC mixture compared to those stabilized
with allograft alone [12]. The stem cell-graft mixture resulted in a two-fold increase in bone
formation at the hip implant site and the test group experienced better overall hip function
after twelve weeks as indicated by greater ground reaction force measurement. MSCs have
also been used to successfully treat critical sized bone defects in a rabbit model after being
cultured on acellular constructs prior to in vivo implantation [13].
As the interest in using stem cells for tissue regeneration increases, a myriad of
approaches have been used to optimize their culture conditions. In vitro test systems are
essential to the development of an optimal tissue-engineered bone graft construct [3, 14].
For bone tissue engineering, the in vitro culture of osteoblasts, from stem cells, has been the
primary focus. Researchers have attempted to increase mineralized matrix production by
differentiating osteoblasts through the use of BMPs, growth factors, and various scaffolds
[15-17]. The research presented herein was centered on the physiological remodeling order
of events: bone resorption by osteoclasts followed by the deposition of mineralized matrix
by osteoblasts (Figure 2.1). These events indicate that the cells responsible for resorbing
bone mineral may also possess the ability to recruit and/or induce osteoblast development
and activation [2, 4].
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Little is known about what factors originating from osteoclasts are responsible for
bringing osteoblasts to the site of bone resorption; however, exposure to these factors either
directly or indirectly could prove to be beneficial in a cell-based bone graft. Incorporating
osteoclast-derived factors into a bone graft system, prior to or at the time of implantation,
could lower the amount of time needed for native bone cells to proliferate and differentiate
at the defect site [2, 4, 18]. Incorporating osteoclasts, or cytokines collected during their
culture, into the system could allow researchers to tailor the rate of differentiation of
mesenchymal stem cells within the graft.

Figure 2.1: Schematic of the interaction between osteoblasts and osteoclasts
during the bone remodeling cycle [3].
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In the body, cytokines and growth factors released into the blood stream are able to
activate surrounding cells; therefore, it is reasonable to believe that these factors are also
released into culture medium during in vitro cell culture. This ‘conditioned medium’ theory
has been previously used to test interactions between various cell types including: adipocytes
and osteoblasts, breast cancer cells and osteoclasts, and calvarial bone cells and osteoclasts
[19-21].
Based on this premise, medium collected from osteoclast cultures was incorporated into
a culture system for developing bone-forming cells [4, 18]. The objective of this preliminary
work was to determine what effect medium taken from differentiating osteoclasts
(conditioned medium) had on mesenchymal stem cells being cultured for osteoblast matrix
production. Due to the differences in culture conditions, culturing these two cell types
separately allowed better characterization of their individual development.

2.2 Methods
Cell Culture & Seeding
All cells were cultured at standard conditions of 37oC and 5% CO2. Mouse monocytes
from the RAW 264.7 cell line (ATCC; Manassas, VA) were seeded into 24-well plates at a
density of 3.8 x 104 cells per well in α-minimal essential medium (α-MEM; Invitrogen;
Carlesbad, CA). RAW 264.7 medium was supplemented with 10% fetal bovine serum (FBS;
Invitrogen), 1% antibiotic-antimycotic, and 10 ng/ml soluble murine RANKL (Peprotech;
Rocky Hill, NJ) to induce osteoclast differentiation. Medium changes were performed every
2-3 days, at which time old medium was collected prior to the addition of new supplemented
medium. The collected medium was passed through a 70 micron filter and termed
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“conditioned medium”. Osteoclast cultures were continuously seeded every 2 days in order
to collect fresh conditioned medium from the cells between 2-4 days of culture. The
conditioned medium was used immediately, as described below.
Multi-potent mouse marrow stromal cells from the D1 cell line (ATCC) were seeded
into 24-well plates at a density of 3.4 x 105 cells per well. Three wells on each plate (OB)
were fed 100% α-MEM with osteogenic supplements (10mM β-glycerophosphate and
50ug/ml ascorbic acid; both from Sigma Chemicals; St. Louis, MO). Three additional wells
(OC) were fed a mixture of 50% conditioned medium and 50% α-MEM with osteogenic
supplements. Medium changes were performed every 2-3 days for the D1 cells over the
course of the study.
Days 8, 14, 21, and 26 were selected as the four time points at which to monitor the
temporal changes in cell differentiation. At each time point, wells of one plate were rinsed
twice with phosphate buffered saline (PBS), and 1.0 ml of distilled water was added to each
well. Following addition of water, plates were placed in a -80oC freezer for storage until the
conclusion of the study. Quantitative assays were performed on all samples simultaneously
after three freeze/thaw cycles.

Qualitative Microscopy
Phase contrast microscopic images were taken of the cells throughout the study prior to
medium changes. An Axiovert 135 inverted microscope (Zeiss; Thornwood, NY) fitted
with an insight color digital camera was used to capture images using SPOT image
acquisition software.
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Metabolic Activity
Metabolic activity of the cells was assessed on samples using alamar Blue TM dye
(Biosource International; Camarillo, CA) on Days 8, 14, 21, and 26. Prior to medium change
on the specified days, 200 µl of Alamar Blue dye (10% of total medium volume) was added
to each well of the Day 26 plate. After gentle mixing, plates were returned to the incubator
for a period of 3 hours, during which time the dye was reduced by metabolically active cells
to produce a color change from a non-fluorescent blue to shades of fluorescent pink.
Following incubation, 200 µl aliquots of media were transferred in triplicate to a black wall,
clear bottom 96-well plate (Corning; Corning, NY). Fluorescence values were read using
excitation and emission filter values of 544 nm and 590 nm, respectively, on a Fluoroskan
Ascent FL fluorometric plate reader (Labsystems; Franklin, MA).

Intracellular Protein Content
The amount of total intracellular protein present in each well was determined using a
BCA protein assay kit (Pierce Biotechnology; Rockford, IL). This protein assay produces a
color change when bicinchoninic acid (BCA) molecules chelate with Cu1+ molecules that
result from the reduction of Cu2+ ions by protein present in test samples. The resulting
purple-colored solution absorbs light at a wavelength of 562 nm. An albumin standard was
diluted according to the manufacturer’s procedure to create a standard curve. A volume of
25 µl of cell lysate was transferred in triplicate from each test sample to a 96-well plate
(Corning). A volume of 200µl of working reagent was added to each well of the 96-well
plate. All plates were gently shaken on an orbital shaker and incubated for 30 minutes at
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37oC. Absorbance values were read at 562 nm on a MRX Revelation microplate reader and
protein values were extrapolated based on the standard curve.

Alkaline Phosphatase Synthesis
An alkaline phosphatase (ALP) assay (Sigma Chemicals; St. Louis, MO) was conducted
on samples at the conclusion of the study. A volume of 100 µl of cell lysate from each test
sample was transferred to a clean plate containing 500 µl of working reagent, made up of
equal parts p-nitrophenyl phosphate and alkaline phosphatase buffer. All plates were
incubated at 37oC for 30 minutes, at which time 0.25N NaOH was added to each well to
stop the reaction. Samples and standards were transferred in triplicate from each well of the
incubated plates for testing within 96-well plates. Absorbance was read at 410nm on a MRX
Revelation microplate reader (Dynex Technologies; Chantilly, VA). Reported ALP values
were normalized with corresponding intracellular protein values.

TRAP Staining
Two methods were used to stain for tartrate-resistant acidic phosphatase (TRAP) activity
by mature osteoclasts. The widely used Sigma-Aldrich TRAP staining results in a dark
purple color when TRAP is present in or around a cell (386-A; Sigma). The recommended
manufacturer procedure was used for RAW 264.7 cell cultures. The traditional TRAP color
change was visible using light microscopy. A second fluorescent-based stain using ELF97
phosphatase substrate (Molecular Probes; Eugene, OR) was combined with a fluorescent
nuclear DNA stain, DAPI (1 µg/ml in PBS, 4',6-diamidine-2'-phenylindole dihydrochloride;
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Roche Diagnostics; Mannheim, Germany), to visualize TRAP activity and cell nuclei
simultaneously. The second method was visible using fluorescence microscopy.

Statistical Analysis
Each data point represents the mean value of n=3 data samples, and error bars denote
the standard error of the mean (SEM). The statistical software SAS® was used to compare
the effects of medium type and time on the metabolic activity, intracellular protein content,
and alkaline phosphatase activity of the mesenchymal stem cells using the Least Squares
Means (LSMEANS) command. A significance level of p < 0.05 was used for all
comparisons.

2.3 Results
Osteoclast Culture
The osteoclast cells were visually observed over the course of the culture period. RAW
264.7 mouse monocytes seeded in 24-well plates proliferated and fused to form large clusters
of cells. The observed clusters of cells formed from cultures of RAW 264.7 exposed to
soluble RANKL were consistent with reports of multi-nucleated cells that are expected for
mature osteoclasts (Figure 2.2) [22, 23]. Both staining methods used for identifying TRAP
positive cells confirmed that TRAP expressive cells were present in the RAW 264.7 cultures
used in this study for collecting conditioned medium (Figure 2.3).
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Figure 2.2: RAW 264.7 mouse monocytes in culture medium containing RANKL
(10 ng/ml) fused to become multi-nucleated cells. Total magnification for all images
is 100x.

Figure 2.3: Left: Traditional TRAP kit stain produced dark purple areas where
TRAP was present surrounding fused cell nuclei. Right: DAPI (blue) stained cell
nuclei surrounded by TRAP positive (green) fluorescent ELF-97 stain. Total
magnification for all images is 320x.

59

Conditioned Medium Study
The D1 multipotent cells from both medium test groups looked similar to
fibroblasts at Day 2 (Figure 1.4: A.1, B.1). By Day 8, the morphology of the OC-fed cells
began to change to a more rounded shape, while the OB fed cells acquired a tightly packed,
polygonal shape more consistent with differentiating bone cells (Figure 2.4: A.2, B.2). There
were marked differences in morphology at Day 26; the cells of the OC fed group were less
dense and included cells with both spindle and rounded morphology, while the OB-fed
group had a more uniform, polygonal appearance (Figure 2.4: A.4, B.4).

Figure 2.4: Morphology of cells grown in 100% osteogenic medium (Top, A.1-4).
Cells grown in osteogenic medium containing 50% osteoclast conditioned medium
(Bottom, B.1-4). Total magnification for all images = 320x.
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Quantitative Assay Results
Metabolic Activity
The metabolic activity of the stromal cells appeared to be unaffected by the type of
medium they were fed (Figure 2.5). There was no significant difference measured between
the cells fed 100% osteogenic medium (OB) and the cells fed osteogenic medium with 50%
osteoclast conditioned medium (OC) at any time point. Both medium groups exhibited
significantly higher levels (p < 0.05) of metabolic activity at Day 14 compared to Days 8 and
26.

Intracellular Protein Content
The cells grown in 50% conditioned medium (OC) contained a significantly (p <
0.05) higher amount of intracellular protein on Days 8, 14, and 26 compared to cells grown
in osteoblast cocktail (OB) alone (Figure 2.6). Both medium groups exhibited a peak in
intracellular protein levels at Day 14, which was followed by a significant drop in protein
production at Day 21.
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Figure 2.5: Metabolic activity levels as a function of time and medium type.
Asterisks (*) denote significantly greater metabolic activity measured for cells at Day
14 (p < 0.05) compared to Days 8 and 26. Each data point represents the mean
value of n=3 data samples, and error bars denote standard error of the mean (SEM).
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Figure 2.6: Intracellular protein levels as a function of time and type of medium.
Asterisks (*) denote significantly higher levels of intracellular protein present in
conditioned medium samples compared to samples grown in osteogenic cocktail.
Pound signs (#) denote a significant peak in intracellular protein level that occurred
at Day 14. Each data point represents the mean value of n=3 data samples, and
error bars denote SEM.

Alkaline Phosphatase Synthesis
Cells grown in OB medium had significantly (p < 0.05) higher levels of ALP synthesis
compared to the cells grown in conditioned medium at each of the four time points (Figure
2.7). A peak value of ALP was observed at Day 21 in the OB test group.
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Figure 2.7: Alkaline phosphatase synthesis as a function of time and medium type.
Reported values were normalized to intracellular protein levels. Asterisks (*) denote
significant differences in ALP levels with respect to medium type (p < 0.05). Pound
signs (#) denote significant increases in ALP measured between Day 14 and Day 21
(p < 0.05). Each data point represents the mean value of n=3 data samples, and
error bars denote SEM.

2.4 Discussion
The discovery of the RANK/RANKL pathway paved the way for successful in vitro
cultures of osteoclasts [24, 25]. An in vitro culture method for osteoclasts was tested for its
ability to produce multinucleated, TRAP positive cells from a murine monocytes cell line.
Previous in vitro work involving osteoclast cultures has been conducted by a number of
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groups using the murine monocytes cell line RAW 264.7 [26-28]. Following a review of
previous two-dimensional culture techniques, the murine cell line seeded at a density of 3.8 x
104 cells per well over a maximum of four days was deemed appropriate for use in this
conditioned medium study [23, 29, 30]. Soluble RANKL was employed to direct these
mononuclear cells to form multinucleated, mature (TRAP positive) osteoclasts.
Morphological examination suggested that the cells did achieve this fusion of nuclei as
described by Vincent and colleagues [23, 29, 30]. A traditional TRAP stain verified that this
osteoclast marker was expressed by the cells and this finding was confirmed using an
additional fluorescent TRAP stain [31]. Thus, this culture method could be used with
confidence for collecting conditioned medium and in future cellular studies involving
osteoclasts.
The term stromal cell is often used interchangeably with mesenchymal stem cell (MSC)
when describing the multi-potent cell type that was used in this study. The murine MSCs
from the current study were characterized over a 26 day period while being cultured in two
different types of medium: 100% osteogenic medium and osteogenic medium mixed with 50
% osteoclast conditioned medium. Qualitative cell morphology images suggested that the
differentiation of the MSCs into osteoblasts was inhibited by the presence of osteoclast
conditioned medium. Osteoblasts change shape as their function changes; growing larger
and more cubical as their level of metabolic activity increases [32, 33]. MSCs cultured in
conditioned medium lacked the polygonal morphology and the tight packing behavior that is
typically described for differentiated osteoblasts on two-dimensional surfaces. The control
group had morphological traits that were much more consistent with what is described for
osteoblasts. Results of the metabolic activity assay were consistent with the morphological
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changes seen between Days 8 and 26, in that cells had a peak in activity at Day 14. This
activity level would be expected to decrease as cells experience a lag in growth size or
proliferation. Cells in the conditioned medium group appeared to be fewer in number and
smaller in size compared to the control at Day 21. The alamarBlue™ assay can also indicate
changes in cell viability, as well as growth, and the two groups may have had different factors
contributing to the drop in activity at the later time point.
Osteoblast differentiation has been divided into three distinct phases that begin with
active proliferation followed by matrix maturation [8, 34]. An intracellular protein assay
performed on test samples indicated that cells grew successfully in each medium type, and
reached a peak level of protein at Day 14 regardless of culture conditions. Researchers have
shown that a direct correlation can exist between the concentration of total protein and cell
proliferation, and the significantly higher levels of total protein recorded for the conditioned
medium group may suggest that this group had a greater level of proliferation over the
course of the study [35]. A higher level of protein could also be attributed to the lack of
cellular spreading and tight packing within the wells, leaving a greater amount of room for
cells to proliferate than was available within wells of the control group.
Results of the ALP assay supported this pattern of differentiation. This marker of
matrix maturation was present in significantly lower amounts in cultures with the highest
levels of total protein. The presence of this surface enzyme, which is expected to be highest
between Days 15-28 in stromal cells differentiating into osteoblast cells, suggested that cells
grown in 100% osteogenic medium were capable of differentiating along an osteogenic
pathway, while cells exposed to conditioned medium did not transition past the initial
proliferation phase of differentiation [36, 37].
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2.5 Conclusions
The results of this preliminary study demonstrated that we can successfully culture
TRAP positive osteoclast-like cells in vitro for use in osteoclast conditioned medium studies.
Optimal osteoclast culture techniques need to be further examined, including the possible
addition of other osteoclastogenic growth factors to promote differentiation [24, 38, 39].
Also, osteoclasts are responsible for resorbing mineralized bone, so culturing these cells on a
mineral based material may have a positive effect on their TRAP activity levels in vitro.
Significant differences in biochemical markers were observed between stromal cells
cultured with and without the addition of osteoclast conditioned medium. Coupled with the
distinct dissimilarity in morphological appearance of each cell group, the results of this study
suggested that stromal cells exposed to conditioned medium collected under these in vitro
conditions were inhibited from transitioning along the osteogenic pathway. These results
may contribute to the development of medium that could be used to control the
differentiation of stromal cells. The ideal combination of cells to include in a cellular-based
bone graft is still to be determined and it may be advantageous to include cells at different
stages of differentiation [40, 41].
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CHAPTER THREE
THE EFFECT OF OSTEOCLAST ACTIVITY ON THE DIFFERENTIATION
OF OSTEOBLASTS FROM STROMAL CELLS

3.1 Background
The link between osteoclastogenesis and osteoblast precursor cells was first observed in
a co-culture system of bone marrow hematopoietic stem cells (HSCs) with stromal cells [1,
2]. Most co-culture experimental setups promote cell-to-cell contact between these two cell
types, based on the belief that this contact is essential to osteoclastogenesis. Although some
studies have indicated that membrane-bound RANKL is more efficient than soluble
RANKL in inducing differentiation of osteoclasts, the process of osteoclast maturation has
been successfully replicated in vitro using a variety of experimental setups [3, 4]. Prior to
1997, work involving osteoclast culture used vitamin D3 (1α, 25-dihydroxyvitamin D3) as the
main medium supplement to induce the formation of multinucleated TRAP positive cells
from monocytes or macrophages [5-7]. The discovery of the RANK-RANKL relationship
resulted in a major shift to include soluble RANKL as a major medium supplement to
induce osteoclastogenesis [8]. This protein is commonly used in conjunction with other
systemic hormones and growth factors such as vitamin D3 and macrophage colonystimulating factor (M-CSF); however, no standards presently exist for culturing osteoclasts in
vitro. The lack of established standards results in a myriad of approaches to culturing
osteoclasts, based on various parameters including cost and culture time [2, 9-11].
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Osteoclast development from HSCs into multinucleated, mature, TRAP-expressing cells
has been examined in detail with regard to what turns these bone resorbing cells ‘on’ and
‘off’. Much of this work has been focused on the development of drugs to treat bone
disorders that employ specific soluble factors to regulate osteoclastogenesis. One significant
discovery, resulting from an in vitro osteoclast culture system, was the identification of a
decoy receptor for RANKL, known as osteoprotegrin (OPG) [9, 12, 13]. By interfering with
the RANK/RANKL binding, OPG can decrease the activation of osteoclasts, resulting in a
decrease in overall bone loss. This mechanism is being explored for the treatment of
patients with imbalanced rates of bone formation and resorption.
Due to the focus on regulating bone loss, less work has focused on what effect
osteoclasts have on developing osteoblasts. It is well established that bone formation by
osteoblasts follows closely behind bone resorption by osteoclasts, but a number of questions
remain regarding how mature or differentiating osteoblasts are recruited to the resorption
site. Pederson and coworkers described both human and animal model studies that led to
the determination that the presence of osteoclasts is essential for normal bone formation,
regardless of the level of activity of the osteoclasts. When normal osteoclast are present, but
unable to resorb, there was no loss in bone formation seen in human models; however when
mice were bred to lack osteoclasts, bone formation was negatively affected [14].
Any effects that osteoclasts have on bone formation may be dependent upon the phase
of osteoclast differentiation. Perez-Amodio and Evert reported that when precursors of
osteoclasts were seeded in direct contact with osteoblasts, the result was a retraction of the
bone forming cells from the growth surface [15]. It was also reported that osteogenic
parameters may be affected by the age of osteoclast cultures when bone marrow stromal
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were studied in a co-culture model [16]. Preliminary findings from our lab indicated that
conditioned medium collected from osteoclasts between 2-4 days of culture inhibited the
differentiation of osteoblasts.
The goal of the work presented here was to determine if osteoclast maturation could be
divided into distinct phases of differentiation. The development of osteoclasts was
examined using a murine monocytes cell line cultured in medium containing either RANKL
(20 ng/ml) or RANKL combined with M-CSF (5 ng/ml). The monocytes were cultured on
both polystyrene tissue culture plastic and on β-tricalcium phosphate ceramic granules to
determine if the growth surface had any impact on cellular activity or TRAP activity.
Following the establishment of phases of osteoclast differentiation, a follow-up study was
performed to determine what effect conditioned medium taken from each phase would have
on the differentiation of osteoblasts from mesenchymal stem cells.

3.2 Methods
Osteoclast Cell Culture & Seeding
Mouse monocytes from the RAW 264.7 cell line (ATCC; Manassas, VA) were
maintained at standard culture conditions of 37oC and 5% CO2. The RAW 264.7 cells were
seeded at density of 3.8 x 104 cells per well directly onto 24-well plate tissue culture plastic or
onto ceramic granules contained within the wells. Osteoclast cultures were tested in three
different medium types: plain α-MEM, α-MEM/RANKL (20 ng/ml), and α-MEM/RANKL
(20 ng/ml)/M-CSF (5ng/ml). All medium types were supplemented with 10% fetal bovine
serum (FBS) and 1% antibiotic-antimycotic. Medium changes were performed every 2 days.
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For the conditioned medium study, RAW 264.7 cells were seeded onto 75 cm2 tissue
culture flasks and maintained in α-MEM supplemented with 20 ng/ml of RANKL. The
cells were seeded as needed to ensure cultures were available from all three phases of
differentiation for collecting conditioned medium. Conditioned medium was collected from
the flasks, filtered to remove any cell debris, and used immediately for feeding osteoblast
cultures, as described below.

MouseTRAP TM Assay
The MouseTRAP Assay (Immunodiagnostic Systems Inc.; Fountain Hills, AZ) was used
to measure tartrate-resistant acid phosphatase 5b (TRAP 5b) activity from osteoclast culture
medium. TRAP 5b is derived specifically from osteoclasts and can be used as a quantitative
indicator of active osteoclast in vitro. Medium samples of 500 µl volume were taken from
each test well every 2 days and immediately stored at -80oC until the conclusion of the study.
The assay was performed according to the manufacturer’s instructions following thawing of
the samples. Test samples, standards and controls were incubated within an antibody coated
plate and any bound TRAP 5b produced a color change in the assay substrate. Absorbance
of test samples and controls were detected at 405nm and compared to a standard curve.

Osteoblast Cell Culture & Seeding
Multi-potent mouse marrow stromal cells from the D1 cell line (ATCC) were seeded in
triplicate (n=3) onto 24-well tissue culture plates at a density of 3.4 x 105 cells per well.
Three wells on each plate (OB) were fed 100% α-MEM with osteogenic supplements (10mM
β-glycerophosphate and 50ug/ml ascorbic acid, both from Sigma). Conditioned medium
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from each osteoclast phase was added to test groups in triplicate. Cells in conditioned
medium wells were fed a mixture of 50% α-MEM with osteogenic supplements and 50%
conditioned medium from either phase 1, 2 or 3 (P1-P3). Medium changes were performed
every 2-3 days for the D1 cells over the course of the study.
Days 7, 13, and 21 were selected as the three time points at which the temporal changes
in cell differentiation were monitored. At each time point, wells of one plate were rinsed
twice with phosphate buffered saline (PBS) and 1.0 ml of distilled water was added to each
well. Following addition of water, plates were placed in -80oC freezer for storage until the
conclusion of the study. Quantitative assays were performed on all samples simultaneously
after three freeze/thaw cycles.

Metabolic Activity Assay
Metabolic activity of the cells was assessed using the alamar Blue TM dye (Biosource
International; Camarillo, CA) at each media change for the osteoclast cultures. During the
conditioned medium study, this assay was performed on Days 7, 14, and 21. Prior to
medium change on the specified days, 200 µl of Blue dye (10% of total medium volume) was
added to each well of a designated plate. After gentle mixing, plates were returned to the
incubator for a period of 3 hours, during which time the dye was reduced by metabolically
active cells to produce a color change from non-fluorescent blue to shades of fluorescent
pink. Following incubation, 200 µl aliquots of media were transferred in triplicate to a black
wall, clear bottom 96-well plate (Corning). Fluorescence values were read at excitation and
emission filter values of 544 nm and 590 nm, respectively, on a Fluoroskan Ascent FL
fluorometric plate reader (Labsystems; Franklin, MA).
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Intracellular Protein Content
The amount of total intracellular protein present in each well was determined using a
BCA protein assay kit (Pierce Biotechnology; Rockford, IL). This protein assay produces a
color change when bicinchoninic acid (BCA) molecules chelate with Cu1+ molecules that
result from the reduction of Cu2+ ions by protein present in test samples. The resulting
purple-colored solution absorbs light at a wavelength of 562 nm. An albumin standard was
diluted according to manufacturer’s procedure in order to create a standard curve. A volume
of 25 µl of cell lysate was taken from each well for testing within a 96-well plate (Corning).
A volume of 200µl of working reagent was added to each test sample; plates were gently
shaken on an orbital shaker and incubated for 30 minutes at 37oC. Absorbance values were
read at 562 nm on a MRX Revelation microplate reader and protein values were extrapolated
based on values produced by the standard curve.

Alkaline Phosphatase Assay
An Alkaline Phosphatase (ALP; Sigma) assay was conducted on samples at the
conclusion of the study. A volume of 100 µl of cell lysate from each sample well was
transferred to a clean plate containing 500 µl working reagent made up of equal parts pnitrophenyl phosphate and alkaline phosphatase buffer. Plates were incubated at 37oC for
30 minutes, at which time 0.25N NaOH was added to each well to stop the reaction.
Samples and standards were transferred in triplicate from each well of the incubated plates
for testing within 96-well plates. Absorbance values were read at 410nm on a MRX
Revelation microplate reader.
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Calcium Deposition Assay
Calcium deposition was evaluated for the D1 stromal cells during the conditioned
medium study according to the protocol described by Lonza Walkersville, Inc. (Lonza;
Walkersville, MD) [17]. On Days 7, 14, and 21 all culture medium was aspirated and wells
were washed with PBS. Following washing, 0.5 ml of 0.5N HCl was added to each well.
Cells were scraped from the bottom of the well plate and samples were transferred to an
Eppendorf tube for storage. An additional 0.5 ml of HCL was added to each well for
rinsing, and the cellular rinse was added to the storage tubes to ensure all cells were
collected. Samples were stored at -20oC until the conclusion of the study. Prior to
performing the assay, samples were thawed on an orbital shaker for 6-12 hours at 4oC. After
shaking, the tubes were centrifuged at 500g for 2 minutes and supernatant with extracted
calcium was collected and transferred to a new tube. Using instructions from the Stanbio
LiquiColorR Calcio Total Procedure No 0150 (Stanbio Laboratory; Borne, TX), a standard
curve was prepared and used to determine the amount of calcium deposition present in each
sample.

Statistical Analysis
Each data point represents the mean value of n=3 data samples, and error bars denote
the standard error of the mean (SEM). The statistical software SAS® was used to compare
test groups using the Least Squares Means (LSMEANS) command. A significance level of p
< 0.05 was used for all comparisons.
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3.3 Results
Osteoclast Culture
Metabolic Activity on Tissue Culture Plastic
The Blue TM assay revealed that the metabolic activity of RAW 264.7 monocytes
cultured on tissue culture plastic appeared to be unaffected by the type of medium they were
fed. There was no significant difference measured between the test groups at any time point
(Figure 3.1). All medium groups exhibited similar levels of activity throughout the study.
After ten days of incubation all three groups expressed a significant peak in activity, which
was followed by a decline at Day 12. The presence of RANKL with or without M-CSF did
not have an effect on the metabolic activity of the cells when compared to the plain medium.

Metabolic Activity on Ceramic Granules
When cultured on ceramic granules, the RAW 264.7 monocytes had lower levels of
metabolic activity throughout the study compared to those grown on tissue culture plastic
(Figure 3.2). The results of this assay, for the cells grown on ceramic, displayed considerable
similarities to the results from the cells grown on tissue culture plastic, despite the overall
lower levels of absorbance. There were no significant differences in activity observed
between the types of medium. Furthermore, these cultures also experienced a significant
drop in cellular metabolism between Day 10 and Day 12.
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Figure 3.1: Metabolic activity of osteoclasts cultured on tissue culture plastic as a
function of time and medium type. Asterisks (*) denote significant peaks (p < 0.05)
in metabolic activity measured at Day 10 for cells grown in all three types of
medium. Each data point represents the mean value of n=3 data samples, and error
bars denote SEM.
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Figure 3.2: Metabolic activity of differentiating osteoclasts cultured on ceramic
granules as a function of time and medium type. Asterisks (*) denote significantly
greater values (p < 0.05) measured at Day 10 compared to Day 12. Each data point
represents the mean value of n=3 data samples, and error bars denote SEM.

TRAP 5b Activity
The MouseTRAP assay allows users to quantify the amount of TRAP 5b being
synthesized by differentiating osteoclasts during their in vitro culture. The RAW 264.7 cells
were able to successfully synthesize TRAP 5b (Figure 3.3). There were no significant
differences in TRAP 5b levels between medium groups, and there was a large amount of
variability seen in all culture groups. Cells cultured in RANKL appeared to have three
distinguishable phases based on metabolic activity and TRAP activity, regardless of growth

81

surface. These phases were identified as: Days 2-4 (Phase1), Days 5-8 (Phase 2), and Days 912 (Phase 3).
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Figure 3.3: Tartrate-resistant acid phosphatase 5b (TRAP 5b) activity by murine
monocytes as a function of time and growth medium. TRAP activity was measured
for cells grown on ceramic granules and tissue culture plastic. Each data point
represents the mean value of n=3 data samples, and error bars denote SEM.
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Conditioned Medium Study
Metabolic Activity
The metabolic activity of the D1 cells appeared to be unaffected by the type of medium
they were fed during the initial week of culture, as there was no significant difference
measured between the groups at this time point (Figure 3.4). After thirteen days in culture,
all of the medium groups exhibited a significant increase in cellular metabolism when
compared to the initial time point. Both the plain medium (Plain) and osteogenic medium
(OB) groups had slightly higher levels of metabolic activity than the groups fed conditioned
medium at the middle time point.

Figure 3.4: Metabolic activity of D1 stromal cells as a function of time and medium
type. Asterisks (*) denote significantly greater values (p < 0.05) measured at Day 13
compared to Day 7. Each data point represents the mean value of n=3 data samples,
and error bars denote SEM.
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Intracellular Protein Content
The result of the BCA total protein assay (Figure 3.5) revealed that murine stromal cells
fed conditioned medium combined with osteogenic differentiation medium had significantly
higher levels of intracellular protein after thirteen days of incubation compared to groups
not fed conditioned medium. This peak in intracellular protein was followed by a significant
decrease at the final time point, Day 19, regardless of what phase of osteoclast differentiation
from which the conditioned medium was collected.

Figure 3.5: Total intracellular protein levels measured for D1 stromal cells as a
function of time and medium type. Cultures fed conditioned medium from
osteoclasts had significantly (*, p < 0.05) higher levels of protein at Day 13
compared to groups not fed conditioned medium. There was no significance
difference observed between the three conditioned medium groups. Each data point
represents the mean value of n=3 data samples, and error bars denote SEM.
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Alkaline Phosphatase Assay
Alkaline phosphatase (ALP) measurements were taken from plates frozen on Days 7, 13,
and 19 to assess osteoblast differentiation (Figure 3.6). The ALP levels appeared to be
hindered by the addition of conditioned medium to the osteogenic differentiation medium.
The results of this assay revealed that the D1 stromal cells cultured in 100% osteogenic
differentiation medium (OB) expressed significantly greater levels of ALP than either the
plain medium control group or the groups fed osteoclast conditioned medium. An increase
in ALP was observed in the OB medium group over time.

Figure 3.6: Alkaline phosphatase synthesized by D1 murine stromal cells as a
function of time and medium type. Asterisks (*) denote significantly higher levels of
ALP synthesized observed in the 100% osteogenic medium group at Days 13 and 19
(p < 0.05). Each data point represents the mean value of n=3 data samples, and
error bars denote SEM.
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Calcium Deposition
Calcium deposition levels (Figure 3.7) were not significant until Day 19 of the study, at
which point the cells cultured in 100% osteogenic medium, Phase 1 conditioned medium,
and Phase 2 conditioned medium had significantly greater amounts compared to the plain
medium control group. The cells tested in 100% OB medium had significantly higher levels
of calcium deposition compared to all other groups at Day 19.

Figure 3.7: Calcium deposition by D1 stromal cells as a function of time and
medium type. Asterisks (*) denotes significantly greater (p < 0.05) amounts of
calcium recorded in OB, Phase 1 CM, and Phase 2 CM groups compared to the plain
medium control group on Day 19. Each data point represents the mean value of
n=3 data samples, and error bars denote SEM.
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3.4 Discussion
Medium Supplements & Phases of Osteoclast Differentiation
The lack of standards for cell culture techniques requires each research group to
determine the most effective way to perform cellular analysis. There are vast numbers of
protocols described in the literature for in vitro culture of osteoclasts, many of which employ
the use of RAW 264.7 murine monocytes cell line. This cell line has been used extensively in
osteoclast studies, though each group has used a different set of parameters to induce
differentiation [18]. Sighting the wide range of culture conditions described in the literature,
Wittrant and coworkers performed studies to examine the best seeding density for RAW
264.7 cells to examine the biological activities of RANKL and OPG during
osteoclastogenesis. They found that a seeding density of 104 cells/cm2 was more appropriate
than higher densities for this cell line and was chosen as the seeding density for the work
presented here [19]. Another important parameter that varies greatly within the literature is
the concentration of RANKL used in osteoclast medium. Concentrations between 5-200
ng/ml have been used, with little explanation given as to why a specific amount was chosen.
Okamatsu and colleagues used a low concentration, 10 ng/ml, with success in studies of
RAW 264.7 cells, exploring MIP-1γ mRNA expression [20]. The Okamatsu group stated
economy as the basis for choosing this concentration, while others have noted that TRAP
activity of RAW 264.7 cells increased in a dose-dependent manner [18, 21]. Based on the
success of the Okamatsu studies and TRAP staining results obtained during earlier
laboratory tests using a minimal amount of RANKL, 20 ng/ml was determined to be an
appropriate amount of RANKL to use for characterizing osteoclastogenesis over a twelve
day period at a density of 3.8 x 104 cells per well for the work described here.
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A MouseTRAP enzyme-linked immunosorbent assay (ELISA) was used in conjunction
with a metabolic activity assay to characterize osteoclastogenesis using RAW 264.7 cells
cultured in the presence of 20 ng/ml of RANKL. TRAP 5b is a form of TRAP that is
unique to osteoclasts and its activity was measured within samples of medium taken
throughout the course of the study. This bone resorption marker has been used in animal
studies as an indicator of local and systemic bone turnover. Lloyd and coworkers found that
mice injected with soluble RANKL had increased serum levels of TRAP 5b, with
measurement taken using the same MouseTRAP ELISA [22]. These TRAP levels were
accompanied by decreases in bone volume, strength, and density. The relationship between
TRAP serum levels and bone loss in the mice was indicative of osteoclast activation by the
RANKL [22]. In the present study, although not significant, there was an increase in TRAP
activity by cells cultured in medium containing RANKL compared to those grown in plain
α-MEM. This increase was present in all cultures regardless of growth surface. These data
indicated that soluble RANKL was able to activate osteoclasts grown under in vitro
conditions.
Peak values of TRAP and metabolic activity at the middle time point were immediately
followed by a slump in levels, regardless of culture medium or growth surface. Using these
peaks and slumps present within the data, three phases were identified for in vitro osteoclast
differentiation from RAW 264.7 cells in RANKL: Days 2-4 (Phase1), Days 5-8 (Phase 2),
and Days 9-12 (Phase 3). Differentiation phases have been identified for other cell types,
most notably osteoblasts. This information has enabled researchers to gain further insight
into other cellular mechanisms that occur during these phases, such as gene expression.
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Increasing this understanding for osteoclasts and other cell types may lead to better cellular
manipulations for use in a tissue engineering approach to bone regeneration [9].
This research also addressed whether the addition of M-CSF would enhance osteoclast
activity in RAW 264.7 cells. It has been widely acknowledged that RANKL is sufficient to
induce osteoclast differentiation; however, M-CSF has also been identified as a necessary
growth factor to induce complete osteoclastogenesis [11, 12, 23]. The data revealed that
TRAP activity was not significantly affected by the addition of 5 ng/ml of M-CSF to the
osteoclast culture medium. Like RANKL, M-CSF has been used in a wide range of
concentrations, and an increase in concentration may result in a synergistic effect of RANKL
on osteoclast TRAP synthesis. The effect of M-CSF on osteoclasts may be better measured
using factors other than TRAP activity, as it has been reported that M-CSF plays an
important role in the proliferation and resorption activity of mature osteoclasts [24, 25].

Conditioned Medium Study
Following the characterization study of osteoclast cultures, a subsequent study was
performed using conditioned medium collected from the three phases identified for
osteoclasts in the in vitro setup. The coupling pattern of physiological bone formation
following active resorption suggests that osteoblasts may behave differently when exposed to
medium acquired from osteoclasts at different stages of development. The conditioned
medium was mixed with osteogenic differentiation medium to test its effect on the
differentiation of osteoblasts from the stromal/stem cells. Cellular metabolism was not
significantly changed by the type of medium cells were fed, suggesting that cells were capable
of proliferating and differentiating over the course of the study. The conditioned medium
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did not have any major detrimental effect on the overall activity of the cells, as was evident
from the metabolic activity data. An interesting result of this study was the significant
increase in activity that occurred in each medium group between Day 7 and Day 13. These
results indicated that cells from the D1 cell line experienced an initial lag in activity after
seeding on tissue culture plastic, regardless of the growth medium. For groups fed
osteogenic medium (with or without CM), this period of activity that was observed between
the first and second time point may also coincide with the first of three phases of osteoblasts
differentiation that has been described by Owen and coworkers and Deyama and coworkers
[9, 26]. This stage has been marked by active proliferation and expression of Type I
collagen. The complimentary pattern seen in intracellular protein levels for cells grown in
osteogenic medium supports the theory that these groups were experiencing the initial stage
of osteoblast differentiation between the first and second time point (Figure 3.5). The initial
phase of osteoblast differentiation can be further examined in future studies by testing for
the expression of Type I collagen and Runx2, two genes that have been linked to the primary
stage of osteoblast differentiation [9, 26-28].
All three conditioned medium groups displayed significantly higher levels of protein at
Day 13 compared to groups that were not exposed to any conditioned medium, which may
indicate that these cells experienced a period of active growth and/or proliferation during
this time. The phase of conditioned medium did not have an effect on this marked increase
in protein levels. Furthermore, ALP levels measured at the middle time point for
conditioned medium groups were very low, which can also indicate that cells were
experiencing a phase of active proliferation. ALP levels would be expected to be very low in
cells that were proliferating rather than moving into the second maturation phase of
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osteoblast differentiation [9, 28, 29]. Conversely, cells that were fed 100% osteogenic
medium had significantly lower levels of intracellular protein levels than CM groups at Day
13, but expressed significantly greater amount of ALP compared to their CM counterparts.
The second phase of osteoblast differentiation has been shown to correlate with high levels
of alkaline phosphatase activity at approximately Day 14, after exposure to differentiation
cocktail as the cells start laying down matrix in the maturation stage [9, 30]. These data
indicated that cells in pure osteogenic medium were able to transition out of the proliferation
stage.
A calcium deposition assay was employed to further explore differentiation of the D1
cells along the osteogenic pathway. Considered a late stage marker of differentiation,
calcium deposition would be expected to occur following high levels of ALP activity when
cells reach the final mineralization phase, as was the case on Day 19 with cells grown in
100% osteogenic medium. The fact that the high levels of ALP also occurred at this final
time point is an indication that the cultures are made up of a heterogeneous mixtures of cells
that can be simultaneously at different stages of maturation. The Phase 1 and Phase 2
conditioned medium groups did have extracellular calcium levels that were greater than the
plain medium control group, but they were still significantly lower than the osteogenic
medium group that contained no conditioned medium. Again, this small increase in calcium
deposition, despite the very low levels of ALP measured for the CM groups, may indicate
that there were cells at various stages of development contained within the sample groups.
Alkaline phosphatase and calcium deposition values collected via the colorimetric assays that
were used in this study are able to give a good indication of what is occurring within the cell
cultures; however, to further examine these preliminary results it will be important to
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investigate genetic markers specific to each cell type and each phase of differentiation in
order to gain a more in-depth understanding of cellular differentiation in our in vitro system.

3.5 Conclusions
It can be concluded that RAW 264.7 murine monocytes are able to differentiate into
osteoclasts under these culture conditions and that in vitro osteoclast differentiation can be
divided into different phases based on TRAP 5b activity and metabolic activity. The
incorporation of osteoclasts into a cellular based bone graft system has the potential to
increase bone formation at the site of injury by recruiting stem cells capable of producing
bone matrix in the same manner that bone forming cells are recruited to areas of bone
resorption in the bone repair cycle in the body [13, 14]. To test this theory, conditioned
medium taken from each of the three phases of osteoclast differentiation was tested on
differentiating murine stromal cells. Ultimately, the results of the quantitative assays suggest
that osteoclast conditioned medium has a positive effect on the protein levels of D1 stromal
cells, but inhibits the overall differentiation of these cells into osteoblasts. These effects are
not dependent on the phase of osteoclast differentiation that the conditioned medium is
collected from. It has yet to be determined if the in vitro culture of maturing bone cells can
be managed with the use of medium tailored using various growth factors and cytokines.
Kojima and Uemura discuss the importance of improving culture techniques for
mesenchymal stem/ stromal cells before any cell-based bone graft system can be applied in a
clinical environment. They have attempted to improve MSC culture methods through the
use of gene therapy. In the present work we have presented an alternate option that is based
on the well known physiological connections between osteoclasts and osteoblasts [31]. This
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option has the potential to improve specific aspects of osteoblast differentiation (i.e. protein
levels, proliferation) in an in vitro culture system.
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CHAPTER FOUR
ANALYSIS OF BONE MARROW ASPIRATE AS AN OSTEOINDUCTIVE
BONE GRAFT MATERIAL FOLLOWING REAMING
OF THE MEDULLARY CANAL

4.1 Background
Over 2 million bone graft procedures are performed annually worldwide to repair defects
caused by trauma or removal of tumors, or to achieve fusion of spinal vertebrae [1]. Bone
grafts are the second most transplanted material into the body, surpassed only by blood, with
sales that have reached over $1 billion and continue to grow as the global population ages [2,
3]. When possible, transplantation of tissue from the patient’s own body (autogenous) to the
area in need of repair is the preferred method of reconstruction. Autogenous bone grafts
(autografts) are the only clinically available options that possess all four characteristics of an
ideal bone graft, specifically, they promote: osteointegration (union with the host bone),
osteoconduction (support of boney and vascular ingrowth within the graft structure and
onto its surface), osteoinduction (ability to induce differentiation of mesenchymal stem cells
into the osteoblast phenotype) and osteogenesis (ability to induce formation of new bone by
osteoblastic cells present within the graft) [4-6]. Unfortunately, healthy tissue is not always
available for harvest and the surgery required to harvest autograft tissue with conventional
methods causes additional pain and possible complications for the patient [2, 7].
Natural and synthetic options have been developed as alternatives to autografts to
circumvent the associated issues, but most of these lack the osteoinductive properties
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desired by surgeons for optimal fracture repair [8-11]. Allografts are products harvested
from cadaver bones that have been preserved by freeze-drying and then vacuum-packed as
whole or partial bone, morsels, or chips. Accounting for approximately one third of bone
graft procedures in the United States, allografts serve as the preferred substitute to
autografts, due to osteointegrative and osteoconductive characteristics that are comparable
to the autologous tissue grafts [12]. Autografts and allografts are the most widely used
materials, with synthetic bone grafts accounting for only approximately 10% of grafting
procedures worldwide [1]. New tissue engineering techniques, coupled with advances in
biomaterials research, are helping to improve graft options with the goal of someday
replacing the need for autogenous tissue that is the current ‘gold standard’ today [13].
Bone tissue engineering devices combine a scaffold material with viable stem or mature
bone cells in a product that can be implanted into boney defects or around a surgical site
[14]. It is widely recognized that the success of a tissue engineered construct will ultimately
depend on how it can be incorporated into the host tissue [15]. The incorporation of
osteogenic cells and growth factors within a bone graft can improve the graft’s viability and
desired properties; but the optimal mix of cells/scaffold/growth factors has yet to be
determined [16]. One major approach toward solving this engineering problem involves
using the patient’s own cells to regenerate lost tissue. These cells can be harvested through
needle aspiration of bone marrow or from the removal of bone tissue during surgical
reaming. Mesenchymal stem cells (MSCs) derived from bone marrow have been successfully
cultured in vitro but expansion protocols are needed to allow widespread clinical application
[17, 18]. In 1997, Jaiswal and colleagues demonstrated a reproducible technique for
expanding MSCs isolated from the stroma of human bone marrow aspirate (donor ages 10-
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58 years) and differentiating them into osteoblasts [19]. Using medium supplemented with
dexamethasone, L-ascorbic acid, and β-glycerophosphate, an in vitro system was established
for developing osteoblasts from human bone marrow which has seen widespread use in the
scientific community. Similar results have been achieved with rat and chick marrow stromal
cells using these methods [20, 21]. Assays for cell proliferation, alkaline phosphatase activity,
and calcium deposition have been used to analyze MSC commitment into mineral secreting
osteoblast-like cells when cultured under these conditions. The long term goal of employing
an in vitro system with stem cells harvested from various sources is for the development of
regenerative treatments for various bone tissue pathologies [19].
It is believed that the aspirate material obtained from femoral shaft reaming prior to
surgical repair is a source of mesenchymal stem cells with osteogenic potential that could be
used at the surgical site. The aspirate material obtained from the femoral shaft using the
Reamer/Irrigator/Aspirator (RIA) device (Synthes, USA; Paoli, PA) consists of three main
elements: bone fragments, liquid flow-through, and a fat layer. Bone fragments collected
using the RIA device have been used successfully for the treatment of segmental defects
and non-unions [22]. Cells isolated from the liquid flow-through have been successfully
expanded in vitro, and found to possess both osteogenic and chondrogenic potential [23].
The fat layer of RIA aspirate has previously been considered waste and little, if any, work
has been done to further examine this component for practical use. Adipose tissue-derived
stem cells (ATSCs) have become a topic of great interest, due to the discovery that they
possess a level of multipotency similar to that of stromal MSCs [24, 25]. Hence, we
hypothesized that cells could be isolated from the fat layer of RIA aspirate and would have
the capability to be driven down an osteogenic pathway [26, 27].
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The objective of our study was to evaluate the bone fragments and the lipid-rich fat
layer of RIA aspirate for the presence of cells that would express osteogenic markers when
cultured under conditions that have been established in the literature for in vitro
differentiation of osteoblasts from mesenchymal stem cells. Using an initial clinical sample,
we sought to develop a method to isolate cells from the individual aspirate layers and
determine if the isolated cells could be expanded and maintained in vitro. Upon developing
these methods, an investigation was conducted to determine if the cells held any osteogenic
potential for potential incorporation into a cellular based bone graft system.
The study provided preliminary information toward our long term goal of determining
if fatty material obtained during reaming of the medullary canal could be incorporated into
a bone graft system to improve the system’s osteoinductive and osteogenetic capabilities.
4.2 Methods
Institutional Review Board approval was obtained from the Greenville Hospital System
University Medical Center and Clemson University prior to the inception of this study.
Reaming aspirate was collected from one male patient (age 33 years) following patient
consent. The sample was packed on ice in the operating room for transport to a cell culture
laboratory. Upon arrival, the floating fat layer was separated from the rest of the sample by
decanting it into a separate sterile container. Liquid flow-through was aspirated from above
and below the bone fragments and fat layer, respectively, in their individual containers
(Figure 4.1). Upon separation, the liquid flow-through was discarded and the remaining two
layers were processed.
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Figure 4.2: Aspirate Sample. A: Bulk aspirate sample before separation
of layers. B: Fat layer of aspirate before (left) and after (right) separation.
C: Bone fragments of aspirate before (left) and after (right) separation.

Bone & Fat Layer Cell Culture
Bone fragments were rinsed extensively in phosphate buffer saline (PBS) and samples of
approximately 8 ml were transferred to culture flasks and maintained at 37oC and 5% CO2.
Five milliliters of Dulbecco’s Modified Eagle’s Medium (DMEM; Invitrogen Corp.,
Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS) and 5%
antibiotic/antimycotic was added, but not removed, every two days through Day 8 to
promote cellular attachment. Bone fragments were then removed, leaving the attached cells;
medium was replaced every two days.
The bulk fatty tissue was rinsed in PBS and divided for further processing. Samples of
3 grams were minced with a scalpel and placed either directly into tissue culture flasks
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containing DMEM, or into 50 ml vials containing a Type II collagenase mixture (6 ml
supplemented DMEM, 2 mg/ml collagenase, and 2% bovine serum albumin). The vials
were maintained at 37oC for 15 minutes to digest the collagen tissue. Vials were inverted at 5
minute intervals. Samples were transferred to a shaker plate and further digested for 45
minutes at 37oC and 250 rpm. Following digestion, samples were passed through 100 and 70
µm filters in succession and centrifuged to form a cell-rich pellet. The pellet was
resuspended and expanded in DMEM culture medium. Supplemented DMEM was added,
but not removed, every two days through Day 8 from flasks containing explants and
resuspended cells. At Day 8, explants were removed and all cultures continued to be fed
every two days.
Cell morphology of all cell cultures was examined via light microscopy. Cells from
each aspirate layer were frozen at Day 12 for long-term storage in liquid nitrogen. The
frozen aspirate cells were thawed and expanded before use in the differentiation study. An
established human mesenchymal stem cell line (hMSC) was purchased (Lonza Group Ltd;
Switzerland) to serve as a control. The hMSCs were thawed according to manufacturer
instructions at the same time as the aspirate cells and all were maintained at standard culture
conditions.

Differentiation Study
Cells isolated from the bone and fat layer were tested to determine their osteogenic
potential. The human MSC line was used as a control (denoted Stem). Cells from each
group were seeded in triplicate onto tissue culture plates at a density of 1,000 cells per cm2.
Test wells (OB) were maintained in MSC Growth Medium (MSCGM, from Lonza)
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containing osteogenic supplements (dexamethasone, L-glutamine, ascorbate, and Bglycerophosphate). A second set of control hMSCs were maintained in plain MSCGM
(denoted Stem Control).
Days 6, 14, and 21 were selected to monitor the temporal changes in cell differentiation.
At each time point, samples were collected for calcium testing and a plate was frozen at 80oC. Metabolic activity (alamarBlue; Biosource International; Camarillo, CA), intracellular
protein (BCA; Pierce Biotechnology; Rockford, IL), alkaline phosphatase (ALP; Sigma) and
calcium deposition (Ca; Stanbio Laboratory; Borne, TX) assays were conducted on all
samples at the conclusion of the study.

Metabolic Activity
Metabolic activity of the cells was assessed on samples using alamarBlue TM dye
(Biosource International; Camarillo, CA) on Days 6, 14 and 21. Prior to medium change on
the specified days, 200 µl of alamarBlue dye (10% of total medium volume) was added to
each well of the Day 21 plate. After gentle mixing, plates were returned to the incubator for
a period of 3 hours during which time the dye was reduced by metabolically active cells to
produce a color change from non-fluorescent blue to shades of fluorescent pink. Following
incubation, 200 µl aliquots of media were transferred in triplicate to a black wall, clear
bottom 96-well plate (Corning; Corning, NY). Fluorescence values were read using
excitation and emission filter values of 544 nm and 590 nm, respectively, on a Fluoroskan
Ascent FL fluorometric plate reader (Labsystems; Franklin, MA).
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Intracellular Protein Content
The amount of total intracellular protein present in each well was determined using a
BCA protein assay kit (Pierce Biotechnology; Rockford, IL). This protein assay produces a
color change when bicinchoninic acid (BCA) molecules chelate with Cu1+ molecules that
result from the reduction of Cu2+ ions by protein present in test samples. The resulting
purple-colored solution absorbs light at a wavelength of 562 nm. An albumin standard was
diluted according to the manufacturer’s procedure to create a standard curve. A volume of
25 µl of cell lysate was transferred in triplicate from each test sample to a 96-well plate
(Corning). A volume of 200µl of working reagent was added to each well of the 96-well
plate. All plates were gently shaken on an orbital shaker and incubated for 30 minutes at
37oC. Absorbance values were read at 562 nm on a MRX Revelation microplate reader
(Dynex Technologies; Chantilly, VA) and protein values were extrapolated based on the
standard curve.

Alkaline Phosphatase Assay
An alkaline phosphatase (ALP) assay (Sigma Chemicals; St. Louis, MO) was conducted
on samples at the conclusion of the study. A volume of 100 µl of cell lysate from each test
sample was transferred to a clean plate containing 500 µl working reagent made up of equal
parts p-nitrophenyl phosphate and alkaline phosphatase buffer. The conversion of
paranitrophenylphosphate to para-nitrophenol in the samples produces a yellow color
change which is used for quantification by measuring absorbance. All plates were incubated
at 37oC for 30 minutes, at which time 0.25N NaOH was added to each well to stop the
reaction. Samples and standards were transferred in triplicate from each well of the
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incubated plates for testing within 96-well plates. Absorbance was read at 410nm on a MRX
Revelation microplate reader. Reported ALP values were normalized with corresponding
intracellular protein values.

Calcium Deposition Assay
Calcium deposition was evaluated for the cells during the differentiation study according
to the protocol described by Lonza Walkersville, Inc. (Lonza; Walkersville, MD) [28]. On
Days 6, 14, and 21 all culture medium was aspirated and wells were washed with PBS.
Following washing, 0.5 ml of 0.5N HCl was added to each well. Cells were scraped from the
bottom of the well plate and samples were transferred to an Eppendorf tube for storage. An
additional 0.5 ml of HCL was added to rinse each well and was subsequently added to the
storage tubes to ensure all cells were collected. Samples were stored at -20oC until the
conclusion of the study. Prior to performing the assay, samples were thawed on an orbital
shaker for 6-12 hours at 4oC. After shaking, the tubes were centrifuged at 500g for 2
minutes and supernatant with extracted calcium was collected and transferred to a new tube.
Using instructions from the Stanbio LiquiColorR Calcio Total Procedure No 0150 (Stanbio
Laboratory; Borne, TX), a standard curve was prepared and used to determine the amount
of calcium deposition present in each sample.

Statistical Analysis
Each data point represents the mean value of n=3 data samples, and error bars denote
the standard error of the mean (SEM). The statistical software SAS® was used to compare
the effects of medium and time on the metabolic activity, intracellular protein content,
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alkaline phosphatase activity, and calcium deposition levels of the isolated cells and the
control mesenchymal stem cells using the Least Squares Means (LSMEANS) command. A
significance level of p < 0.05 was used for all comparisons.

4.3 Results
Cell Isolation from RIA Aspirate
Viable cells were successfully isolated from both the bone and fat elements of the
aspirate. Microscopic examination revealed that the cells that grew from the osseous
particles, fat pieces, and collagenase treated fat tissue had similar morphology (Figure 4.2).
All of the cells grown in this study had morphologies consistent with previously documented
MSCs cultured on tissue culture plastic; i.e., a rapidly expanding monolayer of adherent
spindle-shaped cells, each marked by a cell body and long thin processes [29-32]. After longterm storage (> 30 days) in liquid nitrogen (-196oC) the cells isolated from both layers of
RIA aspirate remained viable. Upon thawing, outgrowth of the cells was not distinguishable
from that of the hMSCs, which are typically stored in the same manner.
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Figure 4.2: Morphology of cells. A: An established human mesenchymal stem
cell line used as a control. B: Cells isolated from the bone fragments layer of
RIA aspirate. C: Cells isolated from the fat layer of RIA aspirate without the use
of collagenase to digest connective tissue. D: Cells isolated from the fat layer of
RIA aspirate using a collagenase treatment. Microscopic examination showed
that cells grown from osseous particles, fat pieces, and collagenase treated fat
tissue had morphology comparable to cells derived from an established
mesenchymal stem cell line.

Metabolic Activity
All cell groups showed a significant (p < 0.05) increase in metabolic activity over time
(Figure 4.3). Significantly higher overall levels of cellular metabolism were recorded for the
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hMSCs compared to the aspirate cells on Days 9, 14, and 21; but all the groups had overall
increases in metabolic activity with time. A gradual increase was observed over time in all
test groups for each of these parameters, and the rate of increase was similar in each group.

Figure 4.3: Metabolic activity of cells as a function of time and cell origin.
Asterisks (*) denote significantly higher levels (p < 0.05) of metabolic activity
on Day 9, Day 14, and Day 21 compared to cells isolated from aspirate
layers. Each data point represents the mean value of n=3 data samples and
error bars denote standard error of the mean (SEM).

Intracellular Protein
Total intracellular protein levels (Figure 4.4) increased significantly (p < 0.05) for all
groups at each time point, with the exception of the hMSC control group maintained in OB
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medium on Day 21. The hMSCs maintained in plain medium had the greatest amount of
protein overall after 21 days of incubation. Day 6 protein values for cells from aspirate
layers were outside the range of the standard curve and were recorded as zero.

Figure 4.4: Total intracellular protein levels measured for cells as a function of
time and cell origin. Asterisks (*) denote significant (p < 0.05) increases in
protein level over time. Pound signs (#) denote protein levels that were
significantly higher on Day 21 compared to all other groups (p < 0.05). Each
data point represents the mean value of n=3 data samples and error bars denote
SEM.

109

Alkaline Phosphatase Assay
All osteogenic medium (OB) test groups exhibited similar trends in ALP synthesis during
the entire culture period (Figure 4.5). After 21 days, all of the cells cultured in osteogenic
medium had significantly (p < 0.05) greater levels of ALP than those cultured in plain
medium. Most notably, there was no significant difference observed between the cells
isolated from the aspirate layers and the established hMSC line

Figure 4.5: Alkaline phosphatase synthesized by cells as a function of time and
cell origin. Asterisks (*) denote significantly higher values (p < 0.05) of ALP
measured in OB medium groups compared to the plain medium groups
(Control) after 21 days of incubation. Each data point represents the mean value
of n=3 data samples and error bars denote SEM.
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Extracellular Calcium Deposition
All groups had a significant increase in calcium (Figure 4.6) between Day 6 and Day 21
(p < 0.05); however, the only set of cells to have significantly higher levels of calcium than
the plain medium control groups were those isolated from the bone layer of RIA aspirate.
This peak level of calcium deposition was observed at Day 21. Cells fed OB medium also
had higher levels of extracellular calcium compared to the plain medium group, starting on
Day 14; cells isolated from the aspirate bone fragments exhibited the highest levels of this
late stage osteoblast marker at Day 21.
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Figure 4.6: Extracellular calcium deposition by cells as a function of time
and cell origin. Asterisks (*) denote significant increases in calcium
deposition observed between Day 6 and Day 21. Pound signs (#) denote
that cells isolated from the bone fragments of RIA aspirate had significantly
greater amounts of calcium deposition compared to the control groups at
Day 21 (p < 0.05). Each data point represents the mean value of n=3 data
samples and error bars denote SEM.

4.4 Discussion
To our knowledge, we are one of the first groups to consider the fat layer of RIA
aspirate separately from the other layers as a potential source of adult MSCs. The study
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described was conducted on the lipid layer of aspirate, which to date has been of low clinical
interest, and served to as a proof of concept for using this autologous material in tissue
engineering applications. The patient sample described in this work was the first sample
from which cells were successfully isolated and enabled the group to establish standard
methods for handling and processing future patient samples. Samples from the fatty layer
were treated using a technique established by Forest and coworkers for the isolation of
preadipocytes from subcutaneous and intramuscular bovine adipose tissue [33, 34]. Isolating
cells from bulk fat tissue samples by digesting the connective tissue and filtering the cells has
enabled researchers to directly compare different fat depots at the cellular level. This
enzymatic digestion technique has been used successfully to isolate cells from bovine bulk
fat deposits in order to study the effects of various stimuli on the differentiation of
preadipocytes and optimize culture conditions for these cells [33]. In the present study,
viable, proliferating cells were successfully isolated from fat layer of the RIA aspirate using
the collagenase enzyme.
Explant methods have been used extensively to produce cellular outgrowth from bulk
tissue pieces in tissue culture [23, 35, 36]. Both explant and dispersion methods used for
processing the bone and fatty layers result in the successful outgrowth of cells. Cellular
outgrowth also occurs when autograft bone fragments are packed directly into a bone defect,
but this method is limited to small volumes [37-40]. It stands to reason that samples taken
from the fat layer of aspirate have similar cellular activity. Hence, combining aspirate fat
fractions with other graft material may be a simple and clinically relevant method to enhance
graft volume. Dispersion could also be performed in the operating room, in a time efficient
manner, to isolate progenitor cells before inclusion into a bone graft system. Although both
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methods may result in a mixed cell population, a mixed population may be beneficial in
providing a larger number of cells that are undifferentiated and in providing the necessary
complex cellular signaling [41-43]. It may be necessary to store cells isolated from a patient
during femoral reaming for use in a future surgical procedure and tissue engineering
applications, therefore, it is important that the cells isolated from the aspirate layers are able
to maintain their ability to proliferate following standard storage. All of the cellular isolation
methods outlined in this work produced repeatable outgrowth results.
The reamer aspirate may be an untapped source for autologous pro genitor cells that
could aid in bone formation when incorporated into bone grafts. The isolated cells were
subjected to conditions widely recognized for inducing osteogenic differentiation in
precursor cells [23, 24, 26, 44, 45]. Results of the metabolic activity and intracellular protein
assays revealed that all of the cells grew well, regardless of origin or medium type,
throughout the 21 day incubation period. The increase of each of these parameters that was
observed over time, in all test groups, suggests that all of the cells experienced similar rates
of growth. The alamarBlue™ dye and BCA protein assays employed in this study are often
used to evaluate cellular proliferation within an in vitro culture system [46, 47]. The hMSCs
grown in plain medium, for example, had significantly higher levels of intracellular protein
and metabolic activity at Day 21. This result suggests that this group proliferated more over
the course of the study than the other test groups. While a relative comparison can be made
within the study, metabolic activity is determined by measuring the absorbance of medium
samples taken after the cells have been given time to metabolize the dye. This measurement
alone does not specify any particular cellular activity, such as division or proliferation.
Although activity levels in the test groups may be similar, cellular activities may be different
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and further examination of specific activities must be conducted. Similarly, the protein assay
can also be affected by factors other than proliferation, including the osteogenic medium
supplement ascorbic acid, and thus can only be viewed as a relative assessment of growth
within the study. A more quantitative analysis of cellular number must be performed in
order to validate this increased proliferation conclusion in future work [48].
The activity of the alkaline phosphatase enzyme was used as a marker for osteoblast
differentiation in this preliminary study. Synthesis of this enzyme alone does not indicate
osteoblast differentiation, but it is an important initial clue for detecting if cells have the
capability to proceed along this bone cell pathway [19, 44, 49]. ALP is a middle stage
osteoblast differentiation marker and is expected to be highest between Days 15-28 in
stromal cells differentiating into osteoblastic cells [50, 51]. Our hypothesis that cells from
the fat layer of reamer aspirate could be driven down an osteogenic pathway was supported
by the recorded ALP values. ALP activity doubled after two weeks and continued to rise
over the three week period. This pattern of ALP synthesis is consistent with other studies
involving hMSCs differentiating into osteoblasts [52]. The third phase of osteoblast
differentiation, mineralization, would be expected to occur after peak levels ALP are reached
during the maturation phase. Cellular calcium deposition would be expected to occur
following the peak in the release of ALP, and, indeed, the calcium levels in our study were
highest at the final time point. Although the levels of calcium deposition were highest in the
cells isolated from aspirate bone fragments, the cells isolated from the lipid layer did display
a significant increase over the course of the study. These data may indicate that although the
cells from the lipid layer may reach the final phase of osteoblast differentiation, they may do
so at a different rate than cells isolated from the autologous bone chips. Additional time
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points will allow better characterization of differentiation using calcium, which is considered
a late-stage differentiation marker; this marker can be confirmed using histological staining.
Alizarin Red S and Von Kossa stains can be employed to visualize mineralized nodules that
form in vitro [23, 52, 53]. The results of these quantitative assays indicate that all of the cells
fed OB medium were induced along an osteogenic pathway using the specified medium
supplements and culture conditions. This pathway was confirmed by detecting the bone cell
marker alkaline phosphatase and calcium deposition. The combination of ascorbic acid, βglycerophosphate, and dexamethasone used in this study has been used extensively to study
osteogenic differentiation, but an optimal culture system is yet to be established.
Researchers have identified a number of factors that affect the terminal differentiation of
marrow cells into an osteoblastic phenotype including: the dose of these supplements, time
of exposure to these supplements, and the age of the cell population [19-21, 44]. A mix of
proliferating and differentiating cells may be more desirable for bone graft applications than
a pure population of terminally differentiated cells in order to achieve osteoinduction and
osteogenesis at the injury site. The data collected indicate that cells from the bone and fat
layer of RIA aspirate may be induced into osteoblast differentiation at differing rates.
Incorporating both of these layers into a bone graft system could ultimately lead to an
increase in the overall length of time that the graft displays osteoinductive activity.
The results of this pilot differentiation study can be used to determine adequate sample
sizes for future work involving this aspirate material in tissue engineering applications. One
of the major issues with current bone graft options, such as demineralized bone matrix
(DBM), is the inconsistencies that exist within a given batch of the product. Commercially
available DBM products, for example, have displayed significant within-batch variability in
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mineral composition and growth factors. These differences have been linked to disparities
in bioactivity of the products and attributed to inconsistencies observed in clinical results
during their use [54, 55]. In contrast, the use of RIA bone fragments has produced relatively
consistent clinical results when compared to the iliac crest standard [56, 57]. The pilot study
results revealed that the fat layer within-batch variability was on par with the bone layer
within-batch variability.

4.5 Conclusions
The results of this pilot study suggest that cells isolated from both the bone and fat layer
of RIA aspirate have the potential to differentiate along an osteogenic pathway. The results
warrant that further consideration be given to the fat layer of aspirate. Previously considered
waste, the lipid rich fat layer of aspirate collected during reaming of the medullary canal may
be a source of adult mesenchymal stem cells that can be used to stimulate new bone growth
at the site of fracture repair. This potential should be further investigated using the cellular
isolation and differentiation techniques described within this work in future studies with
multiple patient samples. Osteoblast differentiation can be further examined by measuring
the expression of the essential osteoblast related genes such as Runx2, Type 1 collagen,
osteocalcin, alkaline phosphatase, and bone sialoprotein [58]. Although an exact map of
gene expression is unknown, the three main phases of osteoblast differentiation
(proliferation, maturation, and mineralization) have been identified using these gene markers
[59]. Gene expression data, coupled with the cellular assays for bone marker expression and
histology stains for mineralized nodule formation, generate an improved overall
understanding of in vitro osteoblast differentiation from precursor cells [23, 47, 51, 60]. In
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vivo experimentation will be required to determine if the differentiation of osteoblasts from
cells isolated from this aspirate source will ultimately translate into new bone formation
within a bone defect. By combining the bulk material or cells isolated from the fatty layer
with the aspirate bone fragments, the osteogenic potential of RIA autograft may be
enhanced.
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CHAPTER FIVE
OSTEOGENIC POTENTIAL OF CELLS ISOLATED FROM THE LIPIDRICH LAYER OF REAMER ASPIRATE

5.1 Background
Stem cells are a unique set of cells that have the capacity for self-renewal and have not
yet committed to a specific cell type [1-3]. These cells have been shown to be multi-potent,
meaning that they possess the ability to differentiate into a number of different cell types.
Bone marrow is widely used as a source for mesenchymal stem cells (MSCs), which exhibit a
high degree of plasticity and the ability to produce osteoblasts, chondrocytes, adipocytes,
myotubes, and neuronal cells [3, 4]. The application of adult stem cells to bone injury repair
is a major area of interest in orthopedic research because of their multi-lineage
differentiation potential of stem cells, their relative availability and ease of harvest, and their
capacity to undergo multiple replications without losing multi-potent potential [5]. These
traits make them an attractive source for cell-based therapeutic approaches. Several
experiments have demonstrated that bone marrow derived MSCs can be induced to
transform into osteoblasts. These cells are also capable of contributing to bone formation
when cultured on a scaffold prior to implantation into the subcutaneous space in mice and
rats [6]. Adipose tissue is another potential source of stem cells in the body that may
contribute to the formation of bone cells [7]. Cells isolated from bulk adipose tissue have
also shown a multi-potency towards bone, cartilage, and neurons, in addition to fat tissue [4,
8]. For these reasons, it is our belief that the fatty portion of RIA aspirate may be an
untapped source for progenitor cells that could be used at the site of fracture repair.
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A tissue engineering approach to bone repair has emerged, using mature and progenitor
cells for defect repair. Incorporating these cells into an established bone grafting material is
one strategy being explored that has shown great promise [9]. Traditional materials are often
used in this research area, as many are biocompatible, are U.S. Food and Drug
Administration (FDA) approved for select applications, and have previous long-term
success. βeta-tricalcium phosphate (β-TCP) has been applied clinically as a bone graft
substitute in either porous or solid form as granules or blocks. This ceramic contains two of
the main minerals components of bone, calcium and phosphate. Porous (60%) β-TCP
ceramic was marketed by Synthes, Inc. in a granule form that is indicated for use in the
repair of skeletal defects. This material is gradually resorbed by osteoclasts and replaced by
new bone [10]. The rate of resorption of β-TCP is often faster than the rate of new bone
formation, therefore, it is often used as a graft expander with autologous tissue [11]. When
mixed with bone marrow and implanted subcutaneously in rats, ultraporous β-TCP has been
found to produce more bone and osteoblastic cells than DBM [12].
The objective of the present study was to evaluate the fat layer of aspirate obtained from
the femoral shaft using the Reamer/Irrigator/Aspirator (RIA) device (Synthes, USA; Paoli,
PA). After successful isolation, cells from this lipid-rich layer were studied to determine
their osteogenic potential and growth potential on a clinically available ceramic bone graft
substitute. To further characterize the composition of this unique layer of aspirate, gas
chromatography was performed on samples taken from multiple patients to determine and
compare the fatty acid content of the lipid samples. A follow-up differentiation study was
conducted using cells isolated from this patient and a second patient to examine if cells
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isolated from different patients exhibit similar trends in behavior in culture conditions
designed to promote osteogenesis.

5.2 Methods
Institutional Review Board approval was obtained from the Greenville Hospital System
University Medical Center and Clemson University prior to the inception of this study..
Reaming aspirate was collected from one female patient (age 23 years, #5003) and packed on
ice for transport to a cell culture laboratory.

Cell Culture
Samples taken from the fat layer of RIA aspirate were processed according to procedures
outlined in Chapter 4 . Briefly, fat samples were minced and placed into a Type II
collagenase mixture to digest the tissue. Following digestion, samples were centrifuged to
form a cell-rich pellet which was resuspended and expanded in MSC Growth Medium
(MSCGM; Lonza Group Ltd; Switzerland). These primary cells were used in the
differentiation study after two passages.

Differentiation Study 1
Primary cells isolated from the fat layer were tested to determine their osteogenic
potential (Asp). A human MSC line (Lonza) was used as a control (H). Cells from each
origin group were seeded at a density of 1,000 cells per cm2, in triplicate, directly onto either
tissue culture polystyrene well-plates or ceramic granules (0.13 grams, Figure 5.1) that
covered the bottom surface of the wells. Test wells (OB) were maintained in MSCGM
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containing osteogenic supplements (dexamethasone, L-glutamine, ascorbate, and βglycerophosphate). Control groups were maintained in plain MSCGM.
Days 9, 20, and 29 were selected to monitor the temporal changes in cell differentiation.
At each time point a metabolic activity (alamarBlue; Biosource International; Camarillo, CA)
assay was performed, samples were collected for calcium testing, and a plate was frozen at 80oC. Samples were frozen until the conclusion of the study, at which point quantitative
assays were performed on all samples simultaneously. Intracellular protein (BCA; Pierce
Biotechnology; Rockford, IL), alkaline phosphatase (ALP; Sigma), and calcium deposition
(Ca; Stanbio Laboratory; Borne, TX) assays were conducted, as previously described in
Chapters 2 and 3, on all samples after thawing.

Figure 5.1: Ceramic Granules. The β-tricalcium phosphate ceramic
granules of bone void filler, 0.5 - 0.7 mm in size were used in this study
(Synthes, USA; Paoli, PA).
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Fatty Acid Composition
Gas chromatography was used to determine the fatty acid content of samples from the
fatty layer of RIA aspirate from the patient sample used in this study and from three other
patient samples. Lipid extracts were collected from approximately 0.1 grams of bulk fatty
material and transmethylated according to previously modified procedures [13-15]. Analysis
of the fatty acid methyl esters was conducted using a HP6850 (Hewlett-Packard, San
Fernando, CA) gas chromatograph equipped with a HP7673A (Hewlett-Packard) automatic
sampler. Standards (Sigma, St. Louis, MO; Supelco; Matreya, Pleasant Gap, PA) were used
to identify individual fatty acids by comparing retention times. Results are reported as a
percentage of total fatty acids.

Differentiation Study 2
Cells isolated previously from the bone and fat layers of one male patient (age 33 years,
#5002) and cells isolated from the fat layer of the female patient described above (#5003)
were used in a follow-up differentiation study after being stored in liquid nitrogen. The
same human MSC line was used as a control. Cells were again seeded at a density of 1,000
cells per cm2, in triplicate, directly onto polystyrene tissue culture plastic wells. Cells were
maintained under the same culture conditions and grown in the same media, i.e. plain MSCG
and MSCGM supplemented with the osteogenic growth factors dexamethasone, ascorbate,
and β-glycerophosphate. The activity and bone cell marker activity of cells isolated from
two different patients were examined at Days 7, 14, and 21. At each time point procedures
were performed as described in Chapters 2-4 for Differentiation Study 1 (metabolic activity
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assay, calcium testing, and end-point assays). The same quantitative assays were conducted
for both differentiation studies.

Statistical Analysis
The data are expressed as the mean value of three data samples, and error bars denote
standard error of the mean. Statistical analysis was conducted using the Least Square Means
command with SAS statistical software. Differences with p values of less than 0.05 were
considered statistically significant.

5.3 Results
Cell Isolation from Patient #5003
Viable cells were successfully isolated from the fatty layer of the RIA aspirate (Figure
5.2B). Morphological examination of these cells was conducted using light microscopy, and
cell shape was compared to the established human MSC line. All cells displayed fibroblastlike morphologies representative of undifferentiated mesenchymal stem cells (Figure 5.2A).
Cells isolated from the aspirate retained this morphology at initial seeding in OB medium
(Figure 5.2C).
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Figure 5.2: Cell Morphology. A: Control human mesenchymal stem cell line in
Mesenchymal Stem Cell Base Medium. B: Primary cells isolated from aspirate in
Mesenchymal Stem Cell Base Medium. C: Primary cells isolated from aspirate in
Osteogenic Medium. Total magnification for all images is 100x.

Differentiation Study 1
Metabolic Activity
No significant difference in metabolism was detected between cells isolated from the
RIA aspirate and the MSC line (Figure 5.3). This result was the same whether cells were
grown on ceramic or on polystyrene. Additionally, no significant difference was observed
when comparing the two culture surfaces or comparing the plain medium and the medium
supplemented with osteogenic growth factors.

Intracellular Protein
Cells cultured on the ceramic granules, in both types of medium, had significantly (p <
0.05) higher levels of intracellular protein compared to cells grown directly on tissue culture
plastic (Figure 5.4). The protein levels also significantly increased for all of the groups
between Day 9 and Day 20, a result that is expected for actively growing cells.
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Figure 5.3: Metabolic activity of cells as a function of time and cell origin. No
significant difference was observed between cells grown on ceramic granules and
cells grown on tissue culture plastic. Metabolism data was similar for cells
isolated from the RIA aspirate and the established stem cell line. Each data point
represents the mean value of n=3 data samples and error bars denote SEM.
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Figure 5.4: Total intracellular protein levels measured for cells as a function of
time and cell origin. Asterisks (*) indicate that significantly higher levels of
protein were measured in ceramic groups compared to tissue culture plastic
groups (p < .05). A significant increase in protein was observed for all groups
between Day 9 and Day 20. Each data point represents the mean value of n=3
data samples and error bars denote SEM.

Alkaline Phosphatase Assay
An alkaline phosphatase assay revealed data that was contrary to the intracellular protein
data. Cells grown on the ceramic granules expressed significantly lower levels of ALP. Cells
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cultured on polystyrene and maintained in osteogenic medium had significantly higher levels
of ALP than the plain medium, polystyrene groups at Days 20 and 29 (Figure 5.5).

Figure 5.5: Alkaline phosphatase released by cells as a function of cell origin and
culture surface. Asterisks (*) indicate that OB medium groups had significantly
higher levels of ALP than the plain medium groups at Days 20 and 29 (p < 0.05).
Significantly lower levels of ALP were expressed by cells cultured on ceramic
granules compared to those cultured on tissue culture plastic. Each data point
represents the mean value of n=3 data samples, and error bars denote SEM.
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Extracellular Calcium Deposition
Due to the composition of the ceramic granules, the extracellular calcium test was only
run on samples collected from cells grown on tissue culture plastic. Levels of calcium
deposition were significantly higher for cells isolated from the RIA aspirate and cultured in
osteogenic medium at the middle and final time points (Figure 5.6).

Figure 5.6: Extracellular calcium deposition levels of cells grown on tissue
culture plastic. Asterisks (*) indicate that Aspirate OB group had significantly
higher levels of calcium than all other groups on Day 20 and Day 29 (p < 0.05).
Each data point represents the mean value of n=3 data samples, and error bars
denote SEM.
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Fatty Acid Content of Multiple Patient Samples
Gas chromatography analysis exposed the fatty acid content (Figure 5.7) of samples
taken from the lipid-rich layer of RIA aspirate of four different patients (#5001-5004). The
results of this characterization revealed that the fat layer of RIA aspirate of all four patients
had the same four fatty acids present in the highest percentages. In descending order the
four most prevalent fatty acids in all patient samples were: oleic, palmitic, linoleic, and
stearic.
y

Carbon #
12
14
14-1
15
16
16-1
17
18
18-1-T9
18-1-T10
18-1-T11
18-1-C9
18-1-C11
18-1-C12
18-2 Omega-6
20
18-3 Omega-3
18-2-c9t11
22-5 Omega-5
22-6 Omega-3

Common Name
Lauric
Myristic
Myristoleic
Pentadecanoic
Palmitic
Palmitoleic
Heptadecanoic
Stearic
Trans-9 octadecenoic
Trans-10 octadecenoic
Trans-11 vaccenic
Oleic
Cis-11 octadecenoic
Cis-12 octadecenoic
Linoleic
Archidic
Linoleic
CLA cis9 trans11
DPA
DHA
SUM
Other

Sample Number
% of total fatty acid composition
5001 5002 5003
5004
0.189 0.173 0.25
0.15
1.919 1.738 2.30
1.61
0.202 0.055 0.24
0.22
0.341 0.102 0.14
0.09
21.89 23.78 22.14
21.53
2.597 0.528 0.08
0.05
0.59
0
0.33
0.33
8.064 8.668 6.08
3.07
0.55
0
0.00
0.00
0.669
0
2.12
0.00
0.701
0
0.00
0.00
37.45 37.16 36.67
39.50
1.709
0
1.80
1.27
0.567
0
0.36
0.39
15.23 16.14 16.04
18.59
0
0.148 0.56
0.00
0.632 0.75
0.33
0.24
0.354 0.379 0.01
0.02
0.196
0
0.14
0.04
0.189
0
0.01
0.01
94.04 89.62 89.61 87.0999
5.958 10.38 10.39 12.9001

Figure 5.7: Fatty acid content of multiple patient samples taken from the
fatty layer of RIA aspirate. Four fatty acids were most abundant in all
patient samples: oleic, palmitic, linoleic, and stearic (highlighted).
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Differentiation Study 2:
Metabolic Activity
Data from the alamarBlue assay showed that all of the test groups had an increase in
metabolic activity over the course of the study (Figure 5.8). Cells isolated from the bone
particles of patient #5002 had metabolism levels comparable to levels calculated for cells
from the human stem cell line. Significantly (p < 0.05) higher absorbance values were
observed for cells isolated from the fat layer of patient #5003, cultured in OB medium, than
were observed for any other group on Day 14 and Day 21.

Intracellular Protein
Values for intracellular protein levels (Figure 5.9) are extracted using a standard curve;
therefore, negative values represent levels of protein that were less than could be calculated
accurately using the standard equation. Cells from the stem cell line control group and cells
isolated from the fat layer of patient #5003 had the highest levels of intracellular protein
over time. Visual examination of cells confirmed that these two groups also had an
increased number of cells over the course of the study.
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Figure 5.3: Metabolic activity of cells as a function of time and cell origin. Cells
Isolated from patient #5003 had significantly (as indicated by asterisks, p < 0.05)
higher levels of metabolic activity on Day 14 and Day 21 compared to all other test
groups. Each data point represents the mean value of n=3 data samples, and error
bars denote SEM.
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Figure 5.9: Total intracellular protein levels measured for cells as a
function of time and cell origin. Each data point represents the mean
value of n=3 data samples and error bars denote SEM.

Alkaline Phosphatase Assay
Alkaline phosphatase levels were normalized to intracellular protein values (Figure 5.10).
Normalized ALP values show that control hMSCs and cells isolated from the bone particles
of patient #5002 had an initial spike in ALP levels, followed by a steep drop at Day 14. The
cells isolated from the fat layer of patient #5003 increased in ALP levels over time and were
significantly higher than other groups on Days 14 and 21. Negative values reported for ALP
are attributed to the protein values used to normalize ALP activity. Non-normalized values
show an increase in expression over time for all groups (data not shown).
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Figure 5.10: Alkaline phosphatase synthesized by cells as a function of
time and cell origin. Each data point represents the mean value of n=3
data samples, and error bars denote SEM.

Extracellular Calcium Levels
Extracellular calcium deposition (Figure 5.11) was measured after centrifuging the
samples to ensure cell debris did not interfere with the results of the test. For the first two
weeks there were no significant amounts of calcium present in any of the samples compared
to the control group. After 21 days of incubation, cells isolated from the aspirate fat layers
of patient #5002 and patient #5003 had significantly greater amounts of extracellular
calcium present in their samples compared with all other test groups. With regards to
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calcium deposition, it was evident that cells isolated from different patients exhibited very
similar levels of this osteoblast indicator.

Figure 5.41: Extracellular calcium deposition by cells as a function of time and
cell origin. Asterisks (*) denote significant differences in calcium levels
compared to stem cell line and cells isolated from bone fragments (p < 0.05).
Each data point represents the mean value of n=3 data samples, and error bars
denote SEM.
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5.4 Discussion
Previous research has examined the benefits of using RIA-harvested bone particles as
autograft material. Kobbe and coworkers found that the autologous bone granules
facilitated healing of a non-union tibial fracture after the more traditional autograft collected
from the iliac crest had failed in a human patient [16]. In a sheep study, re-implantation of
these particles resulted in callous formation within a tibial defect that had significantly
increased volume stiffness and strength compared to callus formed in the absence of RIA
bone particles [17]. Minimal characterization has been conducted on the bone particles,
which are reamed from cancellous bone, but they have been found to possess higher levels
of growth factors connected to bone formation than material taken from the iliac crest [16].
Additionally, Porter and colleagues have had success growing fibroblastic cells from explants
taken from the bone layer of aspirate [18]. We have been able to achieve similar cellular
outgrowth from the osseous particles and believe that our group is one of the first to also
successfully isolate cells from the fatty layer of RIA aspirate. Our isolation procedure has
produced consistent results. We were able to successfully isolate cells from the fatty layer of
RIA aspirate using the same techniques with multiple patient samples. Cellular outgrowth
was achieved from the fat tissue with and without the use of enzymatic digestion.
Further evaluation of the fatty layer revealed that the bulk material is mainly composed
of palmitic, stearic, oleic and linoleic fatty acids. These four accounted for more than 80%
of the total fatty acid content. This fatty acid composition did not seem to be affected by
the patient’s sex or age. The most abundant fatty acids in our samples, oleic and palmitic,
have also been identified as the most abundant fatty acids in subcutaneous human adipose
tissue and in bone marrow aspirates [19, 20]. Similar fatty acid composition have been
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reported for subcutaneous fat sample taken from various areas of the body [19]. The
significance of the fatty acid composition within the RIA aspirate and within the bone
marrow is being explored to determine if the major fatty acids have any role in bone cells
development. Deshimaru and coworkers report that oleic acid promotes the differentiation
of osteoblast when bone morphogenetic protein-2 (BMP-2) is present in cultures of a mouse
mesenchymal cell line [20]. Oleic acid has also been attributed to increased osteoblast
expression of Type I collagen and fibronectin in in vitro studies using human osteoblast-like
cells [21]. Conversely, studies have found that infants fed formula supplemented with oils
rich in palmitic acid have reduced levels of bone mineral density after 3 and 6 months [22].
The results presented here warrant further investigation into the role of fatty acids in bone
formation.
Cells isolated from the aspirate fat layer grew successfully on three-dimensional ceramic
substrates. Any of the materials currently in use as bone grafts or graft substitutes can
potentially be used as scaffolds for tissue-engineered constructs. The ideal scaffold material
must possess a number of important properties including: ability to induce cellular growth
and new tissue formation, ability to support vascularization in a timely manner, ability to
resorb at a rate consistent with new bone growth, and ability to be readily sterilized [23].
Results of the metabolic activity and intracellular protein assays indicated that the β-TCP
granules supported growth of all of the cells used in the study and could be combined with
RIA aspirate autologous material to form a graft expander.
Cells isolated from the fatty portion of the bone marrow have the capability to mature
along both the adipocyte and osteoblast cell lineages [3]. Although levels of ALP were low
in this preliminary study using cells from the fat layer of RIA aspirate, the β-TCP material
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has been shown to successfully support the growth of bone tissue in vitro [24]. Cells will not
transition along the osteogenic pathway when they are actively dividing; the textured surface
and increased surface area of the ceramic granules may have stimulated higher levels of
proliferation., and, therefore, delayed differentiation and release of the marker for maturing
osteoblasts. This active growth surface may have contributed to the lack of ALP measured
in our studies. Future work will focus on better quantifying cellular growth.
The ideal conditions for storage and expansion of cells for use in tissue engineering
applications is an area of great interest. Liu and colleagues determined that liquid nitrogen
was a reliable storage method for stem cells derived from human lipo-aspirate. Their group
found that this preservation method had no detrimental effect on the ability of the adiposetissue derived cells to proliferate, express osteogenic genes (ALP and osteocalcin), or deposit
calcium after storage. Their cells were cultured in osteogenic medium comparable to that
used in our RIA aspirate studies [25]. Results from our second differentiation study, using
cells isolated from two different patients, revealed that the aspirate cells may have
experienced an initial lag in growth following long-term storage in liquid nitrogen. Cells
were seeded at a low density in order to avoid cell lifting during the 21 days of culture, and
cells were fed differentiation medium at Day 0, which may have contributed to a lag in
proliferation which can result in low intracellular protein values. Also, cells from patient
#5003 were frozen for a shorter period of time than the other cells. Data from this test
group at the initial time points were more consistent with data gathered in previous
differentiation experiments.
It is important to note that RIA aspirate samples do not always contain distinct layers of
fat and bone particles. This was the case with patient #5003. The RIA system can be set up
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to filter bone particles out of the aspirate; if this step is not executed there may be some
mixing of the bone and fat layers. Although the fatty layer was very distinguishable in the
sample from patient #5003, it was not separated from the bone particle with a filter, as was
accomplished with the sample from patient #5002. The higher levels of protein and ALP
activity from the fat layer of patient #5003 may be a result of a synergistic effect that may
occur when there is mixing of these two aspirate layers, and cells are isolated from the
resultant mixture. Synthesis of the osteoblast protein ALP in greater amounts by the cells
isolated from the fatty layer of aspirate than by cells from the purchased cell line indicated
that the aspirate cells may have increased osteogenic potential. The calcium deposition
assay results supported this conclusion. An important observation of the second
differentiation study was the similarities that were displayed for the cells isolated from
different patients. This was particularly evident in calcium deposition data. A major
drawback of current bone graft substitutes is the inconsistent results that have been recorded
with their use, and these data indicate that the cells isolated from the fat layer aspirate may
be capable of more consistent mineral deposition [26, 27].
This preliminary study supports the hypothesis that the fatty portion of RIA aspirate
may be an untapped source for progenitor cells that could be beneficial to bone formation if
introduced at the site of fracture repair. Gaining a better understanding of the potency
potential of cells from this novel source of autologous material will aid in the development
of a cell-based bone graft system that may be used in place of the traditional autograft or the
less osteoinductive bone graft substitutes.
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5.5 Conclusions
The results of this study suggest that cells isolated from the fat layer of RIA aspirate
proliferate on ceramic bone void filler and have the potential to differentiate along an
osteoblast pathway. Generally considered waste in the operating room, the lipid-rich fat
layer of aspirate may be a source of mesenchymal stem cells that could be used to stimulate
new bone growth, alone or in conjunction with currently available synthetic bone graft
material. The fatty layer could also be easily combined with the boney layer of RIA aspirate,
and has the potential to enhance osteogenic growth at the site of repair.
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CHAPTER SIX
EFFECT OF OSTEOCLAST COCULTURE ON THE DIFFERENTIATION
OF HUMAN MESENCHYMAL STEM CELLS GROWN
ON CERAMIC BONE GRAFT GRANULES

6.1 Background
The physiological connection between osteoclasts and osteoblasts, as discussed in
Chapter 1, has been closely examined using in vitro models. These models have consisted of
a variety of configurations, with and without direct contact between the two bone cell types.
Successful co-culture experiments have been conducted on two-dimensional cell culture
plates and on three dimensional substrates. Initial studies performed in our laboratory were
conducted with the two cell types cultured in separate vessels in order to evaluate the effects
of osteoclast conditioned medium on mesenchymal stem cell (MSC) maturation to
osteoblasts (Chapter 2). Results of this work suggested that the differentiation of MSCs into
osteoblasts can be affected by the presence of osteoclast conditioned medium [6]. Briefly,
exposure to conditioned medium had a positive effect on intracellular protein levels of
MSCs, but inhibited activity of the bone cell marker alkaline phosphatase (ALP). Pederson
and colleagues also concluded that osteoclast conditioned medium had no impact on the
activity of ALP by mesenchymal stem cells; however, cellular migration and mineralization
were positively influenced by the conditioned medium [13].
Osteoclast conditioned medium used in these studies was collected from monocytes
differentiating into osteoclasts on two dimensional polystyrene surfaces; however, in normal
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physiological conditions osteoclasts actively resorb three-dimensional bone mineral prior to
the deposition of new bone matrix by osteoblasts[1, 12]. To better model this physiological
environment, ceramic scaffolds have been employed to mimic the mineralized component of
bone tissue for studies examining osteoclast resorption. Loomer and coworkers designed a
co-culture setup based on the theory that osteoclasts may influence bone formation through
excretion of cytokines [10]. The experimental configuration consisted of osteoclast cells
seeded onto mineral coated discs (to promote resorption) that were suspended above
growing stromal cell and separated by a mesh. The porous mesh allowed fluid and cytokine
exchange without direct cellular contact. Loomer’s group concluded that the simultaneous
‘cross-talk’ that occurred between the two bone cell types resulted in the inhibition of both
osteoclast resorption and osteoblast maturation. Initial studies performed in our laboratory
employed a similar design, with osteoclasts suspended in co-culture with MSCs; however,
successful osteoclast proliferation was not achieved. It is believed that the setup had
inadequate area for proper osteoclast development; this deficiency may have been a
contributing factor to the lack of resorption observed in the Loomer study. Tortelli and
colleagues designed a co-culture system of osteoblasts and osteoclasts seeded simultaneously
onto resorbable tricalcium phosphate discs. The three-dimensional culture condition was
found to be advantageous to differentiation and mineral deposition of the osteoblasts and it
also increased osteoclast development [18]. Recent studies have proposed that osteoclast
resorption can induce osteoblast differentiation. Spence and coworkers concluded that
osteoclasts ‘condition’ the surface being resorbed with a bioactive layer that positively affects
the response by osteoblasts [16].
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Based on the works described above, it is our belief that the act of resorbing mineral may
enable osteoclasts to induce osteogenesis. The commercially available β-tricalcium
phosphate ceramic bone graft substitute, chronOS (Synthes, Inc.), contains two of the major
minerals found in bone and is already used clinically for fracture repair. Furthermore, the
resorption of chronOS has been attributed to osteoclasts in vivo. These attributes, coupled
with the availability of the material, made chronOS a desirable substrate to use within this
study. The purpose of our study was to determine if osteoblast differentiation is stimulated
when mesenchymal stem cells are co-seeded with osteoclasts on a three-dimensional
resorbable surface.

6.2 Methods
Cell Seeding
Murine monocytes, which are indicated for use as osteoclast precursor cells (RAW 264.7;
Sigma) were seeded (100,000 cells per well) onto 0.13 grams of ceramic granules (chronOS;
Synthes) contained within 12-well culture plates. The well plates were not tissue culture
treated. To produce osteoclasts, soluble RANK-ligand (RANKL) was mixed with serumcontaining medium at a concentration of 30 ng per ml. A volume of 2 ml of the solution
was added to each well. Culture medium was changed every 48 hours for the duration of the
study. After four days in culture, human MSCs (hMSCs; PT-2501; Lonza) were added to
the wells (70,000 cells per well) containing the ceramic granules pre-seeded with RAW 264.7
cells. Four additional groups of hMSCs were seeded onto granules contained within 12-well
non-tissue culture treated plates, as outlined in Table 6.1. Manufacturer recommended
mesenchymal stem cell growth medium (MSCGM) was used as ‘plain medium’. MSCGM
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supplemented for osteogenesis (10mM B-glycerophosphate, 50ug /ml ascorbic acid, and 0.1
µM dexamethasone) was used as osteogenic medium (OB). Medium was removed and
replaced every 48 hours for all test groups. All plates were kept under the standard culture
conditions of 37oC and 5% carbon dioxide (CO2).

Test Group
Plain
OB
OBR
OBOC
preOC

Table 6.1: Description of Study Test Groups
Cell Types and Medium used within Each Test Group
Cells
Culture Medium
Human mesenchymal stem cells
MSCGM : Plain mesenchymal stem cell growth medium
OB medium: MSCGM supplemented with 10mM BHuman mesenchymal stem cells
glycerophosphate, 50ug/ml ascorbic acid and 0.1 µM
dexamethasone
OB medium supplemented with 30 ng per ml soluble
Human mesenchymal stem cells
RANKL
Osteoclast precursor cells co-seeded OB medium supplemented with 30 ng per ml soluble
with hMSCs
RANKL
Osteoclast precursor cells seeded
OB medium supplemented with 30 ng per ml soluble
four days before addition of hMSCs RANKL

Cell Tracker™ Probes
CellTracker™ fluorescent probes (Molecular Probes; Eugene, OR) were used to
visualize each cell type with fluorescent microscopy. These trackers pass through cellular
membranes and are retained by living cells. The probes remain visible for approximately 72
hours. CellTracker™ Green CMFDA (cat. Number C2925) was applied at a concentration
of 20 µM to RAW 264.7 osteoclast precursor cells; the Red CMTPX (cat. Number C34552)
was applied at a concentration of 20 µM to the hMSCs. The manufacturer staining protocol
was used in this study. Briefly, the dyes were diluted to a final working concentration of 20
µM in serum-free medium and warmed to 37ºC. At cell seeding time, the dye solution was
added to a monolayer of cells growing in a tissue culture flask. After 45 minutes of
incubation at 37ºC, the dye solution was replaced with warm serum-containing MSCGM and
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allowed to incubate for an additional 30 minutes. Following the final incubation, cells were
rinsed with phosphate buffered saline (PBS) solution, trypsinized to release them from the
surface of the culture flasks, and seeded onto ceramic granules as described in the previous
section. Images of the cells were taken using a Zeiss Axiovert 40 cFL microscope (Carl
Zeiss MicroImaging, Inc.; Thornwood, NY). Digital images were captured using an
Axiocam mRc5 camera and AxioVision Rel 4.6 software, both from Zeiss.

LIVE/DEAD® Viability Assay
Cell viability was assessed on Day 8 and Day 17 via fluorescence microscopy. Cells
cultures were exposed to cell-permeable calcein acetoxymethyl (calcein AM; Molecular
Probes) and ethidium homodimer-1 (EthD-1; Molecular Probes). Green-emitting calcein
AM (excitation 485 ±10 nm) is retained within live cells while EthD-1 produces red
fluorescence (excitation 530± 12.5 nm) in damaged or dead cells after binding to nucleic
acids. After rinsing with PBS, a solution of 20 µl EthD-1 and 5 µl calcein AM per 10 ml of
PBS was added to the wells designated for the LIVE/DEAD® assay. After 30 minutes of
incubation at 37ºC, cells were imaged using a Zeiss Axiovert 40 cFL microscope (Carl Zeiss
MicroImaging, Inc.) with an Axiocam mRc5 camera and AxioVision Rel 4.6 software, both
from Zeiss.

PicoGreen Assay
The Quant-iT™ PicoGreen® dsDNA assay kit from Molecular Probes (P7589;
Molecular Probes) was used to quantify the amount of DNA present in the test samples.
This method employs a fluorescent nucleic acid stain that is excited at 480 nm and
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specifically targets double-stranded DNA contained within cell nuclei. Cell quantities were
calculated using a standard curve generated by plotting the fluorescence emission intensity
(520 nm) versus DNA concentration of a set of known standards. On Days 1, 4, 8, and 16,
samples were frozen in 1ml of 1X TE Buffer (10mM Tris-HCl, 1mM EDTA, pH 7.5) for
use in PicoGreen® analysis. At the conclusion of the study, a working aqueous solution of
Quant-iT™ PicoGreen® reagent diluted (1:200) with 1X TE buffer was added, at a quantity
of 200 µl, to each well of a black 96-well plate containing 2µl aliquots of thawed test samples.
After 5 minutes of incubation, fluorescence intensity values of the samples were read with a
Fluoroskan Ascent® FL fluorometric plate reader (Labsystems; Franklin, MA). Excitation
and emission values used for reading were 480 nm and 540 nm, respectively. All samples
were tested in triplicate and results are reported as the calculated mean of n=3 samples.

Metabolic Activity
Metabolic activity of the cell cultures was assessed via the alamarBlue assay, as described
previously in Chapter 2. The assay was performed every four days, beginning on Day 2, in
order to ensure that residual dye was removed from the wells and that each reading was
conducted on culture medium that was in culture for two days. All samples were tested in
triplicate and results are reported as the calculated mean of n=5 samples.

Alkaline Phosphatase Assay
Designated plates were frozen on Days 4, 9, and 17 for use in this end-point assay. After
three freeze-thaw cycles, the alkaline assay was performed at the conclusion of the study as
described previously in Chapter 2. All samples were tested in triplicate and results are

155

reported as the calculated mean of n=5 samples. Reported values were normalized to
intracellular protein levels.

RNA Isolation
RNA isolation was performed using the “Purification of Total RNA from Animal Cells
Using Spin Technology” protocol described in the QIAGEN RNeasy® mini kit manual
(QIAGEN; Valencia, CA). On Days 4, 9, and 17, RNA isolation was performed on five
samples within each test group. Buffer RLT from the kit was mixed with 10 μl per ml of βmercaptoethanol (β-ME) prior to use. A volume of 350 μl of Buffer RLT was added to all
wells containing test samples, to lyse the cells. After addition of Buffer RLT, samples were
placed on an orbital plate shaker for 2.5 hours before continuing with the isolation
procedure. This modification to the manufacturer procedure was developed to increase the
efficiency of RNA isolation from cells attached to ceramic granules. Sample lysates were
homogenized using QIAshredder spin columns supplied in the kit, by centrifuging for 2
minutes at full speed (14,000 RPM). An equal amount of 70% ethanol was added to each
homoginized lysate (350µl) and mixed thoroughly. Following transfer to an RNeasy® spin
column, samples were subjected to a series of centrifuge cycles with appropriate buffers
(Appendix A). RNase free water (50 μl) was used to elute the RNA from the spin columns,
and capturing the eluent and RNA in collection tubes. RNA samples were stored at -80ºC
until analysis.
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RNA Analysis
RNA sample quantities and integrity were checked using an Agilent 2100 Bioanalyzer
with an RNA 6000 Nano Assay Kit (Agilent Technologies; Palo Alto, CA) prior to
conducting RT-PCR analysis. Isolated RNA samples were processed according to the
manufacturer’s protocol on RNA 6000 Nano LabChips® (Appendix B). RNA
concentration values were calculated on the bioanalyzer using Agilent 2100 Expert Software
and reported as ng per ml. Samples with an RNA Integrity Number (RIN) of 6 or greater
were used for PCR analysis.

Real-Time Quantitative RT-PCR
The following phenotype-specific genes were chosen to identify osteoblast maturation:
runx2, alkaline phosphatase (ALP), and bone sialoprotein (BSP). Forward and reverse
primers (5’→3’) were chosen for each gene of interest from published studies that have
determined genetic expression using the same cells lines employed in the present work
(Table 6.2). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a reference
gene. All custom 25nmole DNA oligonucleotide primers were purchased from Integrated
DNA Technologies (Coralville, IA).
Gene
Runx2
ALP
BSP
GAPD
H

Table 6.2: Primer Sequences Used in SYBR Green PCR
Forward Primer Sequence 5’ to 3’
Reverse Primer Sequence 5’ to 3’
GACGAGGCAAGAGTTTCACC
TGGAGCTTCAGAAGCTCAACACCA
AATGAAAACGAAGAAAGCGAAG

ATGAAATGCTTGGGAACTGC
ATCTCGTTGTCTGAGTACCAGTCC
ATCATAGCCATCGTAGCCTTGT

GCACCGTCAAGGCTGAGAAC

ATGGTGGTGAAGACGCCAGT
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Reference
[8]
[9]
[9]
[8]

Real-time, one-step RT-PCR was conducted with the Quantifast™ SYBR® Green RTPCR kit (cat. No. 204154; QIAGEN; Valencia, CA) using the reaction mix according to
volumes listed in Table 6.3. All primers were diluted to a final concentration of 30 pmol/µl
and RNA samples were diluted to 10 ng /µl. No-template and minus-RT control samples
were mixed using RNase-free water instead of template RNA and RT mix, respectively.
Both controls were included in each set of PCR samples. All kit components (Master Mix,
template RNA, RNase-free water and RT Mix) were stored at -20ºC and maintained on ice
during the procedure. RNA samples were thawed on ice before aliquoting into individual
PCR vessels. All vessels were vortexed before being placed in the real-time cycler.
All PCR reactions were conducted on a Rotor-Gene RG-3000 (Corbett Research;
Sydney Australia) using Rotor-Gene 5.0.28 software (Corbett Research). The real-time
cycler was programmed as outlined in Table 6.4. A melting curve analysis was performed
with the software during each run to verify the primers’ specificity to the target genes.

Table 6.3 SYBR Green Reaction Setup
Component
Volume/Reaction Final Concentration
(µl)
2x QuantiFast SYBR Green
12.5
1x
RT-PCR Master Mix
Forward Primer
1
1µM
Reverse Primer
1
1µM
QuantiFast RT Mix
0.25
100ng/reaction
Template RNA
10
RNase-free water
0.25
Total reaction volume
25 µl
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Table 6.4: Real-time Cycler Conditions
Time
Temperature
Additional
(ºC)
Comments
Reverse transcription
10 min
50
Hold
PCR initial activation
5 min
95
Hold
step
Two-step cycling
Denaturation
10 s
95
Combined/annealing
30s
60
Data acquired during
extension
this step
Number of cycles
40
Step

RT-PCR Analysis
The mRNA levels for each gene of interest were calculated using the comparative
Ct method, also known as the delta delta Ct (ΔΔCT) method. Means ± standard error of the
mean were calculated from five samples (n=5). The threshold for determining Ct values was
taken from the linear region of the dRNA vs. cycle number plot, using a linear scale. The
GAPDH CT values were used as the reference in the equations:
ΔΔCT = Δ Ct, sample – Δ Ct, control

(Equation 6.1)

Δ Ct, sample = Δ Ct, target - Δ Ct, reference

(Equation 6.2)

Δ Ct, control = Δ Ct, target - Δ Ct, reference

(Equation 6.3)

Day 9 plain medium (Plain) values were used to calculate the ΔCT control values. Final
relative gene expression ratio data were determined using the equation:
Relative Expression Ratio = 2–ΔΔCT

159

(Equation 6.4)

MouseTRAP™ Assay
An enzyme-linked immunosorbent assay (ELISA) specific to osteoclast secreted tartrateresistant acid phosphatase isoform 5b (TRAP) was used to examine osteoclast activity.
Samples for use in the ELISA were taken during medium changes from the test groups that
contained RAW 264.7 cells OBOC and preOC. Medium samples were stored at -80ºC until
the conclusion of the study. The protocol and reagents supplied with the MouseTRAP™
assay (Immunodiagnostic Systems Ltd; Fountain Hills, AZ) were used in this study. The
Anti-MouseTRAP Antibody was reconstituted in 10.5 ml of distilled water and added
(100µl) to appropriate wells of the Antibody Coated Plate. The plate was then incubated for
one hour at room temperature, on a shaker plate(IKA Vibrax VXR; IKA Works;
Wilmington, NC). Following incubation, the plate was washed manually with the Wash
Buffer solution. To wash, 250µl of Wash Buffer were added to each well of the plate with a
multichannel pipette & then decanted. This wash was repeated four times. Calibrator and
Control solutions were added (100 µl) to the designated wells of the Antibody Coated Plate,
in duplicate. Aliquots of the collected medium samples (25µl) were also added to the plate in
duplicate, mixed with 0.9% NaCl (75 µl per sample). The assay Releasing Agent was added
to all wells of the plate (25 µl), followed by another hour of incubation at room temperature
on a shaker plate. A volume of 100 µl of fresh Substrate solution (2 Substrate Tablets in 10
ml Substrate solution, all supplied) was added to each well after washing (x4). After addition
of the Substrate, the plate was sealed with an adhesive cover and placed in a cell incubator
for 2 hours at 37ºC. Next, a Stop Solution was added to all of the wells (25 µl) and the
absorbance of each sample and control was measured at 405 nm after mixing. A standard
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curve was developed using the Calibrator solutions and was used to determine the
concentration of TRAP in the test samples.

Statistical Analysis
Each data point represents the mean value of n=3 data samples, and error bars denote the
standard error of the mean (SEM). The statistical software SAS® was used to compare the
effects of medium and time on the metabolic activity, intracellular protein content, alkaline
phosphatase activity, and calcium deposition levels of the isolated cells and the control
mesenchymal stem cells using the Least Squares Means (LSMEANS) command. A
significance level of p < 0.05 was used for all comparisons.

6.3 Results
Cell Tracker™ Probes
Both the RAW 264.7 osteoclast precursor cells (green) and hMSCs (red) were visible on
the ceramic granules after uptake of the Cell Tracker Probes. The RAW 264.7 seeded prior
to the addition of hMSCs were still present at the time that the stem cells were introduced.
Co-seeding was successfully achieved with the two cell types and images of both cell types
attached to the ceramic granules were captured using fluorescent microscopy (Figure 6.1).
Bothe cell types were still present at 72 hours; however, the green probe was faded and less
visible in the images.
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LIVE/DEAD® Viability Assay
All five test groups had viable cells covering the ceramic granules through the 17 day
study (Figure 6.2). Cultures of hMSCs fed osteogenic medium supplemented with RANKL
(OBR) had larger number of dead cells (red) present at Day 17 than the other test groups.

PicroGreen® Cellular Proliferation Assay
The number of cells calculated for each of the test groups increased significantly (p <
0.05) between Day 1 and Day 16 of the study (Figure 6.3). As expected, the data indicated
that the group pre-seeded with osteoclasts (preOC) contained a greater number of cells
compared to all other groups 24 hours after the addition of the mesenchymal stem cells.
The addition of RANKL to osteogenic medium had a significant (p< 0.05) effect on the
proliferation of hMSCs after eight days in culture, when osteoclasts were not present. The
OBOC group had a significantly (p<0.05) greater number of cells present on Day 4 and Day
8 compared to all other groups; however, no significant differences were detected between
the groups at Day 16. Both groups that contained osteoclasts displayed a significant increase
in proliferation between Day 4 and Day 8 of osteoclast culture (corresponding to Day 1 and
Day 4 of preOC group), which was followed by a gradual decrease.
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Figure 6.1: Cell Tracker™ Probes Images
Living human mesenchymal stem cells (MSC, red) and RAW 264.7osteoclast
precursor cells (OC, green) in culture on ceramic bone graft granules. Top left: OC
cells (green, Day 4) 24 hours after addition of MSCs (red). Top right: MSCs and
OCs 24 hours after simultaneous seeding. Bottom: MSC and OC seeded 72 hours
after simultaneous seeding. Scale bar is 100µm
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Figure 6.2: LIVE/DEAD Cell Viability Images. Viable/live
(green) and damaged/dead (red) cells stained on ceramic granules on
Day 8 (left) and Day 17(right). Scale bars are 100µm
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Figure 6.3: PicoGreen® Cellular Proliferation Assay. Calculated cell
number as a function of time for each test group. Asterisks (*) highlight that
significantly greater number of cells were present in all samples on Day 16
compared to Day 1. The OBOC group had significantly greater number of
cells on Days 4 and 8 compared to all other groups (#, p < 0.05). Each data
point represents the mean value of n=3 data samples, and error bars denote
SEM.

Metabolic Activity
Four of the test groups had significant increases in metabolic activity (Figure 6.4)
between Day 2 and Day 17: Plain, OB, OBR, and OBOC. As expected, a high level of
metabolic activity was recorded for the pre-seeded osteoclast group two days after the
addition of the hMSCs. This initial activity was followed by a significant decrease in activity
within the preOC group. The pre-seeded group also had a spike in activity on Day 17,
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returning to a level that was almost equivalent to Day 2 values. There was no significant
difference in metabolic activity between the five test groups.

Figure 6.4: Metabolic Activity via alamarBlue™. Metabolic activity
levels as a function of time and culture condition. Asterisks (*) denote a
significant increase in activity occurred between Day 2 on Day 17 in four of
the test groups. The groups with both cell types (OBOC, preOC) had
significantly greater levels of activity compared to the single-cell type groups
at Day 1 (#, p < 0.05). Each data point represents the mean value of n=5
data samples and error bars denote SEM.
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Alkaline Phosphatase Assay
Results of this colorimetric assay (Figure 6.5) showed that the groups given
osteogenic medium had significantly higher levels of ALP activity on Day 17 compared to
Day 4 (p < 0.05). At Day 17, the level of ALP was significantly greater in the OB group
compared to the other culture conditions. Interestingly, the two groups that contained
osteoclasts (OBOC and preOC) had the lowest levels of ALPdetected throughout the course
of the study.

Figure 6.5: Alkaline Phosphatase Activity
Alkaline phosphatase activity as a function time. Asterisks (*) highlight that
osteogenic medium groups had significantly higher levels of ALP on Day 17
compared to Day 4 (p < 0.05). Groups that contained osteoclasts (OBOC, preOC)
had lower levels of ALP overall than the other groups which contained only hMSCs.
Each data point represents the mean value of n=5 data samples and error bars
denote SEM
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RT-PCR Gene Expression
The RNA isolation procedure did not yield enough RNA to test all of the samples
with RT-PCR. Gene expression data was collected for all test groups on Day 9, but was only
available for three of the groups on Day 17. Reported data values are relative to Day 9 Plain
medium test samples that were used as the control in Equations 1-4. The highest value of
Runx2 expression was recorded in the hMSC samples that were given osteogenic medium
(OB) for 9 days. This group had significantly (p < 0.05) higher levels compared to the
hMSCs that were co-seeded with osteoclasts (OBOC). The samples that contained
osteoclasts expressed the lowest levels of Runx2. No other significant difference in Runx2
expression was observed between the groups.
Calculated levels of ALP expression were not significantly different between the
groups on Day 9. Levels for this marker were highest on Day 9 for the hMSCs cultured in
osteogenic medium without osteoclasts. After 17 days in culture, both groups containing
hMSCs in culture with osteoclasts (OBOC and preOC) had significantly (p < 0.05) greater
levels of ALP expression compared to hMSCs cultured in the absence of osteoclasts (OBR).
Levels of BSP followed a similar pattern as alkaline phosphatase; cells grown without
osteoclasts had significantly higher levels (p < 0.05) at Day 9 while cells in co-culture
expressed significantly higher levels of BSP after 17 days in culture.
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Figure 6.6: Runx2 expression as a function of culture condition and
time for hMSCs. All levels are relative to calculated expression of hMSCs
cultured in plain medium (Plain) for 9 days. Each data point represents the
mean of five values, and error bars denote SEM.
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Figure 6.7: Alkaline phosphatase expression as a function of culture
condition and time for hMSCs. All levels are relative to calculated
expression of hMSCs cultured in plain medium (Plain) for 9 days. Asterisk
(*) denotes significantly greater levels of ALP expression compared to the
OBR (no osteoclasts) group on Day 17. Each data point represents the
mean of five values, and error bars denote SEM.
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Figure 6.8: BSP expression as a function of culture condition and time for
hMSCs. All levels are relative to calculated expression of hMSCs cultured in plain
medium (Plain) for 9 days. Asterisks (*) highlight the significantly greater levels of
BSP expression for hMSCs grown alone in osteogenic medium with RANKL
compared to cells grown in co-culture. Pound signs (#) highlight that the co-culture
groups had significantly greater levels of expression after 17 days than the OBR
group. Each data point represents the mean of five values, and error bars denote
SEM, p < 0.05.

TRAP Activity
The concentration of TRAP released into the culture medium samples by osteoclasts
is represented in Figure 6.8. Both sets of conditions, osteoclasts pre-seeded and those
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seeded simultaneously with mesenchymal stem cells, expressed similar levels through 8 days.
After Day 8 the cells pre-seeded on the ceramics had levels outside the detectable range of
the standard curve (negative values). Conversely, the TRAP levels of osteoclasts seeded at
the same time with MSCs steadily increased through Day 17.

Figure 6.8: TRAP activity by osteoclasts as a function of time.
Osteoclasts seeded simultaneously with mesenchymal stem cells (♦, OBOC)
exhibited a steady increase in TRAP levels after eight days in culture.
Osteoclasts pre-seeded on ceramics four days before the addition of
mesenchymal stem cells exhibited a decrease in TRAP released over the
course of the 17 day study (■, preOC). No significance was measured
between the two groups (p=0.08) Each data point represents the mean of
n=5 values.
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6.4 Discussion
In the present study, an in vitro co-culture model was used to examine the effects that
osteoclasts have on the differentiation of osteoblasts. This work was conducted with cells
seeded onto a clinically available ceramic bone graft substitute that is resorbed by osteoclasts
in vivo. Preliminary work was conducted with a different co-culture setup that did not result
in active osteoclast growth. Fluorescent CellTracker™ Probes (Molecular Probes) and
digital imaging enabled us to ensure that RAW 264.7 osteoclast precursor cells were present
on the ceramics before hMSCs were added to the preOC group. The probes also made it
possible to ensure that both cell types were able to attach to the ceramic substrates when
seeded simultaneously in the OBOC group (Figure 6.1). After 72 hours, the probes were no
longer visible and the LIVE/DEAD assay was used to confirm that cells in all of the test
groups remained viable, proliferated, and remained attached to the ceramic granules
throughout the duration of the study (Figure 6.2). Work conducted with cells grown in a
monolayer on two-dimensional tissue culture plastic surfaces has been limited by the
tendency of the cells to proliferate to confluence and then detach from the surface. Seeding
density is often a limiting factor with two dimensional studies that extend beyond 14 days.
This limitation may have a negative effect on data collection. For a material to be
considered for tissue-engineering applications, it must be able to support viable cells
throughout the bulk, both under in vitro conditions and eventually when implanted into a
bone defect. Often bone graft material is packed around an implant or into a defect site
where the fluid flow around it may be limited. The fluorescent images taken during this
study of the cells growing on chronOS granules show that these three-dimensional
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substrates were able to successfully support the cells for 17 days under static culture
conditions with limited fluid exchange.
In our previous studies, cellular proliferation was estimated based on intracellular protein
levels. While this method is a good indicator of cell proliferation, it is more of a qualitative
assessment and can be influenced by factors other than cell number. The PicoGreen® assay
gives a quantitative assessment of cell number based on the amount of double stranded
DNA present in the samples and is insensitive to other cell growth indicators. Work done
by Forsey and Chaudhuri has shown that PicoGreen® yields accurate results of cell number
when cells are seeded within a three dimensional construct [2]. Their results have also
indicated that using standards of known cell numbers to generate a standard curve, as in the
present study, is more accurate than using the λDNA standard that is supplied in the kit [2].
Further supporting our conclusion that the three-dimensional ceramic granules were
successful within this co-culture model, the results of this quantitative assay indicated that
the cells in all five of the test groups significantly increased in number over the course of the
17 days (p < 0.05). Visual examination of the cells via the LIVE/DEAD assay confirmed
this result (Figure 6.2); the ceramic granules were covered in live cells after 8 days in culture
and remained covered through Day 17. The pattern of proliferation and metabolic activity
observed for the groups that contained osteoclasts were consistent with our previous work
that identified three phases of osteoclast differentiation (Chapter 3). Metabolic activity levels
supported the results of the PicoGreen assay; however, the fluctuation in activity observed
by the co-cultured cells was a good indication that metabolic activity is influenced by factors
other than cell number.
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Much of the work conducted involving RANKL and bone cells have focused on the
expression of this molecule by osteoblasts and how it affects osteoclastogenesis and bone
resorption [3, 14]. Little work has been conducted that isolates RANKL as an additive that
may affect osteoblast differentiation. Lin and coworkers concluded that the addition of
RANKL had no impact on the proliferation of primary osteoblasts isolated from rat
calvariae [7]. Conversely, in a 2003 review, Teitelbaum and Ross first hypothesized that
RANKL may activate osteoblast precursor cells and promote osteoblast formation [17]. The
results of these past studies indicate that the effect of RANKL on osteoblasts is dependent
on their level of maturation. Our data indicate this peptide had an effect on the proliferation
of osteoblast precursor cells, but this effect was not immediate. An effect on the activation
of BSP gene was also seen. This interesting finding will ensure that a control RANKL
supplemented group will be incorporated into future studies to isolate how this peptide
contributes to the changes seen in mesenchymal stem cells when osteoclast medium
(containing RANKL) is incorporated into co-culture models.
The osteogenic medium had a significant impact on the synthesis of alkaline phosphatase
by the MSCs when measure with the colorimetric assay, as illustrated by the OB test group.
When RANKL was introduced as a variable, the cells did exhibit an increase in ALP levels
over time, but at lower amounts than when it was not present in the medium. As discussed
previously, exposure to osteoclast conditioned medium has been found to inhibit the
expression of the ALP bone cell marker [6, 13]. Even with the change of exposure from
conditioned medium to direct contact, the presence of osteoclasts inhibited the activity of
ALP by the mesenchymal stem cells in this study. In both instances, there was an inverse
relationship between cellular proliferation and ALP activity, which supports the theory that
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MSCs will not transition along an osteogenic pathway if they are at a stage of active growth.
Enzyme production occurs after active propagation of the cells has decreased.
In addition to the colorimetric assay used previously and within this study to determine
the cellular expression of alkaline phosphatase by MSCs, RT-PCR was employed to better
examine ALP activation at the molecular level. While it is hard to draw a direct correlation
and firm conclusions without successful isolation of all of the RNA samples, both methods
suggest that there was an increase in expression of this marker over time. It is important to
note that gene expression data collected using PCR indicates that the target gene has been
activated; however, it is not necessarily indicative of the amount of cellular synthesis of the
protein. Liu and coworkers observed differences between real-time PCR results and results
of other quantitative methods used to determine expression of Type I collagen at the
biological level. These differences were attributed to the fact that the cell has the ability to
move the protein to extracellular space from intracellular space without upregulating genetic
expression of the protein at the RNA level [8].
The patterns of expression observed for the other two osteoblast specific markers were
consistent with what would be expected for differentiation of osteoblasts, although further
work must be conducted to improve RNA isolation techniques. Runx2 is a transcription
factor specifically expressed by osteoblast progenitor cells. This factor has a major role in
the regulation of other osteoblast-expressed genes, such as osteocalcin, which are initiated
during the early stage of differentiation [5, 9]. The levels of Runx2 decreased between Day 9
and Day 17 in this study, suggesting that the gene was present early in the study. Successful
isolation of RNA from samples within the first week of culture will be essential to better
determine if the expression of this gene is affected by the presence of osteoclasts.
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Expression of bone sialoprotein is expected to be highest in differentiating osteoblasts after
two weeks in culture [8, 15], and levels were highest at Day 17 in the present study. Both coculture groups had significantly greater levels of expression of BSP on Day 17 compared to
the group seeded without osteoclasts (OBR), but there was no significant difference between
the two groups that contained osteoclasts.
BSP is associated with the mineralization that occurs during the late stage of osteoblast
differentiation and it has also been linked to the formation of mineral in cancer tumors [4,
19]. Osteoclast conditioned medium has been linked to increased levels of bone
mineralization, and these data suggest this important mineralization gene may be influenced
by the presence of osteoclasts. Curiously, osteoclasts may be able to influence factors from
the initial and final stages of osteoblast differentiation without having a significant effect on
markers linked to the middle stage. These findings warrant future investigations.
The maturation of osteoclasts was assessed by testing TRAP 5b activity levels in culture
medium collected during the 17 day study. In the physiological environment it is likely that
osteoclasts reach a point of terminal activity before bone formation occurs, and this study
was used gain insight into the effect that the osteoclast terminal differentiation may have on
MSCs that are integrated into the bone graft material. TRAP levels were negligent in the
preOC group, but a steady increase in activity was observed for the osteoclasts seeded
simultaneously with hMSCs. Gori and colleagues have previously documented the positive
effect that undifferentiated MSCs in co-culture with mouse marrow cells have on the
formation of osteoclasts. Their work was conducted on two-dimensional plates; these data
show that the same positive effect, as measured by TRAP activity, was observed on threedimensional substrates.
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Even though other researchers have observed an increase in osteoblast differentiation on
surfaces that have been pre-seeded with osteoclasts, pre-seeding the ceramics with
osteoclasts did not have an impact on any of the osteoblast markers tested in this study
when compared to the OBOC group. Spence and colleagues removed the resorbing
osteoclasts from the ceramics before introducing osteoblast precursor cells. It was thought
that the act of trypsinizing and removing the osteoclasts from the three-dimensional
substrates would affect the ability of the MSC to attach, but removal of osteoclasts may be
explored in the future.

6.5 Conclusions
This study was developed to gain further insight into the role that osteoclasts may
play on the differentiation of mesenchymal stem cells when incorporated into a bone graft
system. We have shown that the addition of RANKL and the presence of osteoclasts can
positively influence the proliferation of mesenchymal stem cells and their expression of latestage markers osteoblasts differentiation markers in an in vitro model. Findings from this
study, coupled with the knowledge obtained from our previous work will aid in the
development of a clinically viable mesenchymal stem cell based bone graft system.
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CHAPTER SEVEN
CONCLUSIONS
A successful tissue-engineered construct should offer a more desirable alternative to the
autologous bone grafts that are currently the preferred choice of surgeons. Ideally, these
constructs will possess the osteoinductive and osteogenic properties that are desired by
surgeons for proper repair. The incorporation of cells and growth factors within a synthetic
bone graft may improve its performance, but the optimal mix of cells, scaffold, and growth
factors has yet to be determined. We hypothesized that osteoclasts may play an important
role in the recruitment of mesenchymal stem cells (MSCs) to areas of bone resorption and
the differentiation of osteoblasts and their presence would have an effect on the
differentiation of osteoblasts.
To test this hypothesis, in vitro conditions were developed for culturing cells capable of
expressing the osteoclast-specific molecule TRAP 5b. Osteoclast differentiation was
achieved in vitro using cells from a mouse monocyte cell line cultured in medium and
supplemented with RANKL. It was determined that the differentiation cycle of the bone
resorbing cells could be divided into three phases. Medium from these successful osteoclast
cultures was collected and used as ‘conditioned medium’. MSCs from an established cell line
were inhibited from differentiating along an osteogenic pathway when exposed to the
osteoclast conditioned medium. Osteoclast conditioned medium did, however, have a
positive effect on intracellular protein levels of MSCs. The phase of osteoclast
differentiation from which condition medium was collected had no bearing on the overall
effects of the conditioned medium on the development of the osteoblasts.
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The effects of osteoclasts on the differentiation of MSCs were observed on both twodimensional and three-dimensional surfaces. Osteoclasts grew successfully on 3-D ceramic
substrates and expressed increased levels of TRAP 5b activity compared to osteoclasts
grown on tissue culture plastic. When seeded directly with MSCs on the 3-D substrates, the
osteoclasts had an increase in TRAP activity over time if seeded simultaneously. The coculture setup also resulted in increased proliferation of MSCs. Late stage osteoblast
differentiation markers (i.e. calcium, BSP) were also positively affected by both conditioned
medium from, and direct co-culture with, osteoclasts. The addition of RANKL to the
culture medium to induce osteoclastogenesis appears to be a factor in the observed
responses by MSCS, but it is not the only factor influencing the mesenchymal stem cells.
Osteoclasts were shown to have an influence on the development of mesenchymal stem cells
into osteoblasts when cultured in vitro.
The aspirate material obtained from the femoral shaft using the
Reamer/Irrigator/Aspirator device (Synthes, USA; Paoli, PA) was evaluated as a potential
untapped source of mesenchymal stem cells that could aid in bone formation when
incorporated into bone grafts. The fat layer of aspirate, typically discarded in the clinic, was
the focus of this work. Cells were successfully and consistently isolated from the fatty layer
of RIA aspirate using the same techniques with multiple patient samples. Cellular outgrowth
was achieved from the fat tissue with and without the use of enzymatic digestion of the
connective fatty tissue of the lipid-rich layer. Fat layer and bone layer aspirate cells had
morphology comparable to those from an established mesenchymal stem cell line. Further
characterization performed on the fat layer from multiple patient samples showed that the
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fatty layer of aspirate was mainly composed of four main fatty acids: oleic, palmitic, linoleic,
and stearic.
The isolated cells were successfully expanded using in vitro cell culture techniques and
they were viable in culture following liquid nitrogen storage. Cells isolated from both the
bone and fat layer of reamer aspirate grew successfully on tissue culture plastic and on 3-D
ceramic substrates. When grown on ceramic granules, cells isolated from the fat layer of
aspirate expressed higher levels of intracellular protein compared to those grown on tissue
culture plastic but had lower levels of the osteogenic marker alkaline phosphatase, suggesting
that the cells proliferate at higher levels on the ceramics, delaying differentiation. Aspirate
cells were, however, able to express the osteoblast cell markers alkaline phosphatase and
calcium when cultured in osteogenic differentiation medium on 2-D surfaces and, after
extended time periods, on 3-D surfaces. The expression of these markers suggests that these
isolated cells have the potential to be driven towards osteoblast phenotype when exposed to
select conditions. The results of this work indicate that the fatty layer of RIA aspirate may
be a new untapped source for autologous progenitor cells with bone forming capabilities.
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CHAPTER EIGHT
RECOMMENDATIONS FOR FUTURE WORK

1. Additional in vitro osteoclast cell studies should be performed with human osteoclast
precursor cells to determine if the cellular behavior observed in this work using
murine cells is consistent across species.
2. Future co-culture studies should be performed within a bioreactor with dynamic
fluid flow to allow continuous replenishment of supplements. A bioreactor
environment will minimize rapid consumption of available nutrients that may occur
win a static system and will facilitate the removal of cellular waste products.
3. Additional methods should be employed to more comprehensively assess osteoblast
differentiation from mesenchymal stem cells. Recommendations include:
a. Use immunofluorescence to detect osteoblast markers such as collagen Type
I and alkaline phosphatase.
b. Examine the expression of additional osteoblast makers, including
osteocalcin, with RT-PCR techniques.
4. Improvements should be made to ensure successful isolation of RNA from cells
growing within three-dimensional constructs. Recommendations include:
a. Mechanically grind the substrates prior to performing the RNA isolation.
5. All aspirate studies should be repeated with more patient samples and an increased
sample size should be used within each study. Studies should be performed that
compare the activity of cells isolated from multiple patients.
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6. Cells isolated from the reamer layers should be further characterized to determine if
they are a pure population of mesenchymal stem cells. Additional characterization
techniques could include:
a. Identification of cell surface expression of MSC markers (i.e. CD34, CD105,
CD44, etc.) by flow cytometry.
b. Immunocytochemical staining, with antibodies against mesenchymal stem
cells surface molecules, coupled with fluorescent microscopy to visualize
fluorescently labeled cells.
7. Cellular studies to examine what effect the bulk fatty layer material has on MSCs
when mixed with RIA bone fragments should be performed.
8. After additional in vitro studies are performed with both bulk aspirate material and
cells isolated from the material, in vivo animal studies should be performed to
determine if the incorporation of these components into a bone graft system will
result in increased bone formation at the site of bone repair under physiological
conditions.
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Appendix A
Protocol: Purification of Total RNA from Animal Cells Using Spin Technology*
*Adapted from the QIAGEN RNeasy® mini kit manual
For use with the QIAGEN RNeasy Mini Kit
Catalog no. 74106 (2009)
Use pipettes and tips designated for RNA work
Before starting:
 Mix 10 μl β-mercaptoethanol (β-ME) per 1 ml Buffer RLT in a fume hood, wearing
appropriate protective clothing
 Add 4 volumes of 100% ethanol to the Buffer RPE supplied in the kit
Procedure for cells grown on three-dimensional substrates:
1. Disrupt the cells by adding Buffer RLT.
a. Use a volume of Buffer that will cover the substrates: 350 µl or 600 µl
2. Mix samples on an orbital shaker for 2 hours
3. Pipette cell lysate directly into a QIAshredder spin column supplied within a 2 ml
collection tube, and centrifuge for 2 min at full speed (14,000 rpm on Eppendorf
centrifuge).
a. Use one QIAshredder column per sample
b. SAVE flow-through
4. Add 1 volume of 70% ethanol to the homoginized lysate (Step 3 flow-through), and
mix well by pipetting. Mix any precipitate that forms.
5. Transfer up to 700 µl of the ethanol mixture to an RNeasy spin column supplied
within a 2 ml collection tube. Centrifuge for 15s at ≥10,000 rpm.
a. DISCARD flow-through.
b. REUSE collection tube
6. Add 700 µl Buffer RW1 to the RNeasy spin column. Centrifuge for 15s at ≥10,000
rpm.
a. Remove the RNeasy spin column from the collection tube so it does not
contact the flow-through.
b. DISCARD flow-through
c. REUSE collection tube
7. Add 500 µl Buffer RPE to the RNeasy spin column. Centrifuge for 15s at ≥10,000
rpm.
a. DISCARD flow-through
b. REUSE collection tube
8. Add 500 µl Buffer RPE to the RNeasy spin column. Centrifuge for 2 min at
≥10,000 rpm.
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a. Remove the RNeasy spin column from the collection tube so it does not
contact the flow-through.
b. DISCARD flow-through and collection tube
9. Place the RNeasy spin column in a new 1.5 ml collection tube. Add 50 µl of RNasefree water into the spin column. Centrifuge for 1 minute at ≥10,000 rpm. Flowthrough contains the RNA.
10. Repeat Step 9 if expected RNA yield is > 30 µg
11. Store RNA samples at -80°C
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Appendix B
Protocol: RNA 6000 Nano Assay Protocol*
*Adapted from the Agilent RNA 6000 Nano Assay manual
For use with the Agilent RNA 6000 Nano Assay kit
Catalog no. 5065-4476 (10/2009)
Use pipettes and tips designated for RNA work
Always keep the samples and ladder on ice
Before starting:
 Remove RNA 6000 Nano LabChip kit from the 4°C fridge equilibrate at room
temperature for 30 minutes.
 Remove the ladder aliquot from -20°C freezer and thaw it on ice.
 Set water bath temperature to 70°C
Procedure:
Preparing the Gel
1. Place 550 µl of RNA 6000 Nano gel matrix (red top vial) into the top receptacle of a
spin filter (supplied).
2. Centrifuge the spin filter for 10 minutes at 4000 rpm (Eppendorf microcentrifuge).
3. Aliquot 65 µl filtered gel into 0.5 ml RNase-free microcentrifuge tubes (supplied).
Store the aliquots at 4 °C and date. Use gel aliquots within one month of
preparation.
Preparing the Gel-Dye Mix
1. Protect the RNA 6000 Nano dye (blue top vial) from light at all times.
2. Vortex the dye for 10 seconds; spin down.
3. Add 1 l of dye to a 65 µl aliquot of filtered gel.
4. Vortex to ensure proper mixing (visually inspect).
5. Centrifuge the gel-dye mix for 10 minutes at room temperature at 14,000 rpm
(Eppendorf microcentrifuge).
6. Use the centrifuged mixture within 24 hours.
Loading the Gel-Dye Mix
1. Always use a new RNA Nano chip, removed from a sealed bag.
2. Place the chip on the Priming Station. Priming station base plate should be in C
position.
3. Pipette 9 µl of the gel-dye mix into the bottom of well marked G. to prevent air
bubbles from forming in the chip, do not ‘blow’ the last bit of mix from the pipette.
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4. Close and latch the Chip Priming Station. With plunger set at 1ml, press plunger
until it is held by the clip and leave for 30 seconds.
5. After 30 seconds, release the plunger from the clip. Wait 5 seconds and return
plunger to 1 ml position.
6. Open Priming Station and pipette 9 µl of the gel-dye mix into the bottom of wells
marked G.
Loading the RNA 6000 Nano Marker
1. Pipette 5 µl of the RNA 6000 Nano Marker (green top vial) into the well marked
with the ladder icon and into each of the 12 sample wells. Add 6 µl of Marker to and
wells that will not be used with RNA samples.
Loading the RNA 6000 Nano Marker
1. Pipette 1.3 µl of thawed RNA 6000 ladder into an RNase-free tube and denature
in the 70°C water bath for 2 minutes.
2. Pipette 1 µl of the denatured ladder into the well marked with the ladder icon.
3. Pipette 1 µl of each RNA sample into the sample wells on the chip (#1-12).
4. Vortex the chip for 1 minute at 2000 rpm on the IKA vortexer with chip
adapter.
5. Analyze within 5 minutes
Chip Analysis in Agilent 2100 Bioanalyzer
1. Place chip into receptacle within the bioanalyzer, it only fits one way. Close the
lid.
2. Select Instrument.
3. Select Assay → Electrophoresis → RNA → Eukaryote Total RNA Nano
4. Set ‘Destination’ for files to be saved.
5. Click START.
6. Data file will be saved in ‘Destination’ folder when run is complete.
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